New strategies for the application of Adeno-Associated Virus type 2 targeting vectors by Goldnau, Daniela
 Dissertation zur Erlangung des Doktorgrades  
der Fakultät für Chemie und Pharmazie 
 der Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
 
New strategies for the application of  
Adeno-Associated Virus type 2 targeting vectors 
 
 
 
 
 
 
 
 
 
Daniela Goldnau 
 
aus 
 
Duisburg 
 
 
2006 
 
  
Erklärung 
Diese Dissertation wurde im Sinne von § 13 Abs. 3 bzw. 4 der Promotionsordnung vom 
29. Januar 1998 von Herrn Prof. Dr. Michael Hallek betreut und von Herrn Prof. Dr. Horst 
Domdey vor der Fakultät für Chemie und Pharmazie vertreten. 
 
 
 
Ehrenwörtliche Versicherung 
Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. 
 
München, am 31.3.2006 
 
 
Daniela Goldnau 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertation eingereicht am: 07.04.2006 
 
1. Gutachter: Prof. Dr. Horst Domdey  
2. Gutachter: Prof. Dr. Michael Hallek 
 
Mündliche Prüfung am: 23.5.2006 
 
 Danksagung 
 
Ich danke Herrn Prof. Dr. Michael Hallek für die Möglichkeit meine Doktorarbeit in seiner 
Arbeitsgruppe durchzuführen und die Bereitstellung eines sehr interessanten Themen- und 
Aufgabengebiets.  
Herrn Prof. Dr. Horst Domdey danke ich, als meinem Doktorvater, für die Möglichkeit in 
der Fakultät der Chemie meine Doktorarbeit anzufertigen.  
Mein besonderer Dank gilt Frau Dr. Hildegard Büning, die diese Doktorarbeit betreut und 
mich vom ersten bis zum letzten Tag begleitet und unterstützt hat. 
Besonderer Dank gilt Prof. Patrick Cramer, der das Genzentrum seit Juni 2004 mit 
innovativer Kraft leitet und die Weiterarbeit an dieser Arbeit in den Räumen des 
Genzentrums ermöglicht hat.  
Mein Dank gilt der Firma Medigene, die ein viel versprechendes Projekt weiterverfolgt 
und unterstützt hat. Besonderer Dank gilt hier Markus Hörer und den Mitgliedern seiner 
Gruppe für kritische und hilfreiche Diskussionen und Unterstützung auch im praktischen 
Bereich.  
Für die Unterstützung bei der Durchführung der Experimente zur Kopplung über 
Maleimide Bindung sowie für anregende Diskussion und die Bereitstellung verschiedener 
Materialien möchte ich mich ganz herzlich bei Dr. Florian Kreppel, Universität Ulm, 
bedanken.  
Bedanken möchte ich mich auch bei meinen Mitstreitern Kerstin und Jan, die für 
Diskussion und auch viel Spaß im Labor gesorgt haben. Ebenso bedanken möchte ich mich 
bei den ehemaligen Mitglieder der AG Hallek, hier insbesondere Kristin und Nadja, die 
mich ebenfalls bis zum Schluss begleitet haben und immer ein offenes Ohr und einen guten 
Rat parat hatten. 
Ein ganz lieber Dank geht auch an Sigi Kastenmüller, Frau Mewes und Frau Fulde, die 
immer eine große Hilfe bei verwaltungstechnischen Dingen waren. 
Innigsten Dank möchte ich meinen Eltern für ihre großartige Unterstützung in jeglicher 
Hinsicht und für alles, was sie mir mit auf den Weg gegeben haben, aussprechen.  
Mein ganz besonderer Dank gilt meinem Freund Torsten, für seine Liebe, Verständnis, 
seine Motivation, Freundschaft und fürs einfach nur da sein. Schön, dass es Dich gibt! 
 Die vorliegende Arbeit wurde in der Zeit von Dezember 2001 bis März 2006 am Institut 
für Biochemie der Ludwig-Maximilians-Universität München unter der Anleitung von 
Prof. Dr. Michael Hallek angefertigt. 
 
 
 
 
 
 
 
Im Verlauf dieser Arbeit wurden folgende Veröffentlichungen angefertigt: 
 
Kerstin Lux, Nico Görlitz, Stefanie Schlemminger, Luca Perabo, Daniela Goldnau, Jan 
Endell, Kristin Leike, David M. Kofler, Stefan Finke, Michael Hallek, Hildegard Büning 
"Green Fluorescent Protein-Tagged Adeno-Associated Virus (AAV) Particles Allow 
the Study of Cytosolic and Nuclear Trafficking"; J Virol. 2005 Sep 79(18):11776-87. 
 
Luca Perabo, Jan Endell, Susan King, Kerstin Lux, Daniela Goldnau, Michael Hallek, 
Hildegard Büning 
"Combinatorial Engineering of a Gene Therapy Vector: Directed Evolution of 
Adeno-Associated Virus"; J Gene Med. 2006 Feb;8(2):155-62. 
 
Daniela Goldnau, Jan Endell, Luca Perabo, and Kathryn White, Jorge Boucas,  
Sibille Humme, Lorraine Work, Hanna Janicki, Michael Hallek, Andrew H. Baker, 
Hildegard Büning 
"HSPG binding properties of Adeno-Associated Virus (AAV) retargeting mutants 
and consequences for their in vivo tropism"; in revision, J Virol, January 2006. 
 
Hildegard Büning, John Nieland, Luca Perabo, Daniela Goldnau, Kerstin Lux, and Michael 
Hallek 
"AAV anti-idiotypic vaccine", eingereicht als Erfindungsmeldung, 2005  
 
 
 
  
 
 
 
 
 
 
 
 
 
"Our deepest fear is not that we are inadequate. Our deepest fear is that we are powerful beyond 
measure. It is our light, not our darkness, that most frightens us. We ask ourselves, who am I to 
be brilliant, gorgeous, talented and fabulous? Actually, who are you not to be?" 
From Nelson Mandela's inaugural speech as President of South Africa - May 1994 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Für meine G oßelternr  
 
 

Summary  1
Summary 
 
Vectors based on adeno-associated virus type 2 (AAV) offer considerable promise 
for the somatic gene therapy of various diseases (e.g. cystic fibrosis, hemophilia B, cancer) 
and new applications such as vaccination. Limitations, however, still exist and require 
further improvements, especially in the field of cell specific gene transfer. The study 
presented here addresses ways of generating an universal rAAV retargeting vector and an 
AAV based anti-idiotypic vaccine approach.  
Due to its primary receptor heparan sulphate proteoglycan (HSPG), wtAAV shows 
a broad tissue tropism. To generate tissue specific rAAV vectors, different targeting 
approaches were used, including the insertion of a targeting peptide into exposed sites on 
the AAV capsid. For in vivo application an universal targeting vector, which does not 
demand the production of a new AAV mutant each time, would be of great advantage. 
Two different strategies were applied for the generation of an universal AAV retargeting 
vector, either containing a polyionic insertion and a cysteine (AAV-Glu) or only cysteine 
flanked by glycines (AAV-Cys), both at the exposed insertion site 587.  
The accessibility and the reactivity of the thiol groups of the inserted cysteine of 
AAV-Glu were demonstrated by conjugation of AAV-Glu to a thiol reactive dye. But 
conjugation to the polyionic ligand SIG could not be verified in transduction experiments. 
AAV-Cys did not show conjugation ability to 5k-Polyethylenglykol-Mal (5k-PEG-Mal) 
ligand. In the following six new cysteine mutants were generated, this time by amino acid 
exchange with cysteine at different exposed sites in the capsid surface. These mutants are 
currently evaluated for their conjugation ability and showed promising results in 
preliminary experiments. 
Many AAV targeting vectors have been generated by peptide insertions at position 
587/588 of the capsid. This is likely to interfere with the heparan sulphate proteoglycan 
binding ability of at least two (R585 and R588) of the five positively charged amino acids 
of the recently identified HSPG binding motif, explaining the ablation of HSPG binding of 
some targeting vectors. In some cases, however, binding was only partially affected, or 
even restored. To investigate molecular mechanisms responsible for these differences, a 
library of AAV capsids mutants carrying insertions of 7 randomized amino acids at 
position 587 were applied to a heparin affinity column to separate binding from non-
binding mutants. This resulted in a model explaining the HSPG binding and non-binding 
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phenotypes of AAV targeting mutants. Furthermore, the inability to bind to heparin/HSPG 
correlated with liver and spleen detargeting in in vivo studies after systemic application, 
suggesting several strategies to improve efficiency of AAV-2 retargeting to alternative 
tissues in the future. 
Many passive immunization approaches using monoclonal antibodies against a 
variety of diseases have reached the drug market in the recent years. Here we present a 
strategy to develop vaccines for active immunization based on anti-idiotypic AAV library 
mutants selected on antibody epitopes. Selections were performed with the AAV library, 
containing a random insertion of seven amino acids at the exposed site 587. Two 
antibodies were tested, the IgE binding antibody Omalizumab (Xolair®) and mouse anti-
KLH IgG, directed against Keyhole Limpet Hemocyanin (KLH). Mutants could be 
selected for Omalizumab as well as for anti-KLH IgG. Two out of three selected sequences 
for Omalizumab showed specificity for the antibody in Dot Blot analysis and four out of 
five on anti-KLH IgG selected sequences demonstrated specificity for anti-KLH. This 
proof of principle indicates that the selection of AAV library mutants on antibodies is in 
general possible and provides the basis for new generation of vaccines. Immunization 
experiments in rabbits are currently ongoing.  
Taken together, these results should be useful for the design and selection of 
improved recombinant AAV vectors for retargeting and a new generation of active 
immunization vaccines. 
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1. Introduction 
1.1. Adeno-Associated Virus as vector for Human Gene 
Therapy 
Presently available gene delivery vehicles for somatic gene transfer can be broadly 
divided into two categories: viral and nonviral vectors (Table 1). The nonviral vectors, also 
known as synthetic gene delivery systems, represent a category of delivery vehicles which 
rely on direct delivery of either naked DNA or RNA with cationic lipids. Nonviral vectors 
do not share the safety risks of the viral transfer systems, but suffer from low efficiency of 
gene transfer and only transient expression of the delivered genes. Based on the nature of 
their genome, viral vectors can be divided into RNA (retroviruses) and DNA (adeno-
associated virus, adenovirus, herpes simplex virus, pox virus) viral vectors. Viruses are 
intracellular parasites that have developed efficient strategies to invade host cells, and in 
most cases, transport their genetic information into the nucleus.  
 
Table 1. Gene Therapy Trials world wide (www.wiley.co.uk/genmed/clinical) 
 
1 Number of clinical trials conducted worldwide (March 2006) 
Vector Trials1 Example of diseases  
Viral    
Adeno-Associated Virus 
(AAV) 38 (3.3%) 
Cystic fibrosis, hemophilia B, 
prostate cancer, neurological 
disorders, muscular dystrophy  
 
Adenovirus 
287 (25.1%) 
Many cancers, peripheral artery 
disease, cystic fibrosis, 
Canavan disease 
 
Herpes simplex Virus 
(HSV) 38 (3.3%) 
Brain tumor, colon carcinoma  
Pox Virus 59 (5.2%) Many cancers  
Retrovirus 
276 (24.1%) 
Many cancers, AIDS, SCID, 
rheumatic arthritis, graft-versus-
host disease, multiple sclerosis, 
osteodysplasia, hemophilia 
 
    
Nonviral    
Gene Gun2 5 (0.4%) Melanoma, sarcoma  
Lipofection3
95 (8.3%) 
Many cancers, cystic fibrosis, 
coronary artery disease, 
restenosis 
 
Naked DNA (plasmid) 
192 (16.8%) 
Many cancers, peripheral artery 
disease, coronary artery 
disease, peripheral neuropathy, 
open bone fractures 
 
RNA transfer 14 (1.2%) Many cancers  
    
Other 136 (12.3%)   
2 DNA coated on small gold particles and shot with a special gun into target tissue 
3 Includes liposomes and various packages of lipid, polymer, and other molecules 
Introduction 6 
The major advantages of viral vectors are their high transduction efficiency and the 
potential stable expression of the therapeutic gene (retroviruses, adeno-associated virus).  
 
A limitation, however, is the risk of toxicity of the vector and induction of 
immunological reactions against the vector (e.g. adenoviral vectors) or its transgene.  
The Adeno-Associated Virus (AAV), which was utilized in the present work, is a 
particularly promising delivery system for human gene therapy and the number of clinical 
trials using AAV based vectors is constantly increasing since 1994, when AAV based 
vectors were utilized in a gene therapy trial dealing with cystic fibrosis (Flotte and Carter, 
1995). One major reason why AAV vectors receive increasing attention is the safety of this 
vector: no known pathogenicity has been related to AAV infection. Moreover, AAV 
vectors are replication deficient and fail to unleash cellular immune responses (Hernandez 
et al. 1999, Joos et al. 1998, Zaiss et al. 2002). This has been attributed to the poor ability 
of AAV to infect dendritic cells (Bessis et al. ), but newer studies show that cell-mediated 
immunity can occur against the AAV capsid and were responsible for the decline of the 
Factor IX transgene gene (Manno et al. 2006) 
AAV, the primary virus, is a member of the parvovirus family. Viruses of this 
family have a single-stranded DNA genome of approximately 5kb and a non-enveloped 
icosahedral capsid. With a diameter of only 18 to 30nm the parvoviruses are among the 
smallest known viruses. For its progeny production adeno-associated viruses naturally 
depend on co-infection of an unrelated helper virus, e.g. adenovirus (Ad), herpesvirus 
(HSV), human cytomegalovirus, or papillomavirus (for review see (Muzyczka and Berns, 
2001). Originally, AAV was found as a contaminant in laboratory stocks of adenovirus, 
hence the name “adeno-associated virus” (Atchison, Casto, and Hammon, 1965; Hoggan, 
Blacklow, and Rowe, 1966). Up to now eleven serotypes (AAV type 1 – AAV type 11), 
which share different levels of sequence homology, have been identified (Gao et al. 2002, 
Gao et al. 2004, Mori et al. 2004). Although the other serotypes have attracted increasing 
attention during recent years, AAV type 2 is the most prominent serotype for gene therapy, 
being the best characterized. All following descriptions will refer to AAV type 2, it will be 
termed AAV throughout this work.  
The life cycle of AAV has two distinct intracellular phases (Figure 1). In the 
absence of co-infection by a helper virus the latent cycle is initiated. AAV enters the cell, 
and after a limited expression of viral regulatory proteins (Rep proteins), the virion 
integrates preferentially into the host genome in the q arm of chromosome 19 at a specific 
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locus (AAVS1). After super-infection with a helper virus, the integrated genome is 
activated by entering the lytic cycle, leading to viral gene expression, rescue and 
replication of the AAV genome with subsequent production of viral progeny (Berns and 
Giraud, 1996). Besides helper virus also genotoxic agents (e.g. UV-irradiation, γ-
irradiation, hydroxyurea, topoisomerase inhibitors, and various chemical carcinogens) can 
support a productive infection (Heilbronn et al., 1985; Russell, Alexander, and Miller, 
1995; Yakobson et al., 1989; Yalkinoglu, Zentgraf, and Hubscher, 1991; Yalklinoglu et al., 
1988). These observations led to the conclusion that the role of helper functions is rather 
the induction of the appropriate cellular milieu (expression of stress response genes) 
required for AAV DNA replication than direct involvement of helper virus gene products 
(Yakobson, Koch, and Winocour, 1987).  
infectionLatent Cycle
ch 19
adenovirus
co-infection
AAV
adenovirus
co-infection
 
Figure 1. The biphasic life cycle of AAV. In the presence of a helper virus, e.g. adenovirus or herpesvirus, 
AAV enters the lytic cycle and undergoes a productive infection. Lacking a helper virus the AAV DNA can 
stably integrate preferentially into chromosome 19 of the host genome (AAVS1). After super-infection with a 
helper virus AAV can be rescued from the latent state and reenter the lytic cycle. (Figure kindly provided by 
Nadja Huttner) 
 
The natural route for AAV infections is assumed to occur via the respiratory or 
gastrointestinal route as is the case for Ad, because in vivo AAV has been typically found 
as a contaminant of Ad isolates (Blacklow et al., 1971). However, it is not yet clear what 
tissue or organ is a preferred site of latency in humans. Nevertheless, recombinant AAV 
vectors have demonstrated infection and long-term gene expression in a wide variety of 
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tissues, including brain, liver, muscle, lung, and retina in animals (Fisher et al., 1997; 
Flannery et al., 1997; Flotte et al., 1993; Kaplitt et al., 1994; Snyder et al., 1997; Xiao, Li, 
and Samulski, 1996). Although AAV is widespread, no disease has been associated with 
the virus (Berns and Linden, 1995). On the contrary, AAV seems to be protective against 
bovine papillomavirus and Ad mediated cellular transformation (de la Maza and Carter, 
1981; Hermonat, 1989; Khleif et al., 1991; Mayor, Houlditch, and Mumford, 1973), and 
seems to have cytotoxic effects in malignant cells (Raj et al. 2001). 
 
 
1.2. Genomic and Structural Organization of AAV 
 
The wild-type AAV (wtAAV) has a single-stranded DNA genome of 4680 
nucleotides and consists of two large open reading frames (ORF). These ORFs are flanked 
by palindromic sequences, the inverted terminal repeats (ITRs) (Figure 2). 
The 145 nucleotide long inverted terminal repeats (ITR) form a T-shaped structure 
on either side of the genome. They contain a Rep binding site (RBS) and a specific 
cleavage site for the bound Rep protein (terminal resolution site, TRS) (Im and Muzyczka, 
1990; McCarty et al., 1994; Snyder et al., 1993; Snyder, Samulski, and Muzyczka, 1990). 
They constitute an important cis-acting signal which serves as origin of replication (ori) 
and primer for initiation of DNA synthesis. Furthermore they are critical for regulation of 
gene expression, and essential for site-specific integration of AAV and rescue of the viral 
genome from the integrated state (Labow and Berns, 1988; McLaughlin et al., 1988; 
Samulski, Chang, and Shenk, 1987). 
The 5’-ORF rep encodes the non-structural, regulatory Rep proteins. Two 
promoters, p5 and p19, direct expression of the rep gene. A common intron results in the 
production of four Rep proteins: p5 promoter controls transcription of Rep78 and its splice 
variant Rep68, whereas transcription of Rep52 and its splice variant Rep40 is controlled by 
the p19 promoter. Rep78 and Rep68 are multifunctional proteins with diverse biochemical 
activities, including DNA binding, DNA ligase, ATPase, DNA helicase, and strand- and 
site-specific endonuclease activities (Im and Muzyczka, 1990; Im and Muzyczka, 1992; 
Smith and Kotin, 2000; Zhou et al., 1999). They are involved in AAV DNA replication, 
transcriptional control and targeted integration. The two smaller proteins, Rep52 and 
Rep40, appear to be involved directly in the accumulation and encapsidation of single-
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stranded genomes into preformed capsids (Chejanovsky and Carter, 1989; Dubielzig et al., 
1999; King et al., 2001; Smith and Kotin, 1998). The Rep proteins can act as both 
repressors and transactivators of AAV transcription by regulating the activities of the three 
viral promoters. In the absence of helper virus, all Rep proteins have been observed to 
repress p5 and p19 transcription (Kyostio et al., 1994).  
The 3’-ORF cap encodes three structural proteins with overlapping amino acid 
sequences, VP1, VP2, and VP3, which form the viral capsid. They are all transcribed from 
the p40 promoter and expressed in a ratio of approximately 1:1:20 (Kronenberg, 
Kleinschmidt, and Bottcher, 2001) and use a common stop codon. The molecular weight of 
VP1, VP2, and VP3 is 90kDa, 72kDa, and 60kDa, respectively. While VP3 alone is 
sufficient for capsid formation and VP2 capsid protein is non essential for viral infectivity 
(Warrington et al. 2004), VP1 is required for viral infection (Hermonat et al., 1984; Smuda 
and Carter, 1991; Tratschin, Miller, and Carter, 1984). 
 
  p5      p19                 p40
Figure 2. Map of the AAV genome. The AAV genome encompasses 4680 nucleotides, divided into 100 map 
units. Indicated are the two inverted terminal repeats (ITRs), the three viral promoters at map position 5, 19, 
and 40 (p5, p19, and p40) and the polyadenylation signal at map position 96 (poly A). The open reading 
frames are represented by rectangles, untranslated regions by solid lines and the introns by carats. Large Rep 
proteins (Rep78 and Rep68) under the control of the p5 promoter and small Rep proteins (Rep52 and Rep40) 
driven by the p19 promoter exist in spliced and unspliced isoforms. The cap genes encoding the three 
different capsid proteins VP1, VP2, and VP3 are under control of the p40 promoter. 
 
The AAV particle has a molecular weight between 5.4 and 6.0 x 106 g/mol (de la 
Maza et al. 1980). Approximately 70% of the mass is protein, and the remaining is DNA. 
AAV particles are very resistant to inactivation. They are stable between pH 3 and 9 and at 
56°C for 60 min. Inactivation of the virus is possible by formalin, β-propriolactone, 
hydroxylamine, and oxidizing agents (Berns et al., 2000). 
ITR   10            20            30            40            50            60             70            80            90 ITR
polyA
Rep 78 
 
Rep 68 
 
Rep 52 
 
Rep 40 
 
VP1 
 
VP2 
 
VP3 
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While the atomic structures of related autonomous parvoviruses, including canine 
parvovirus (CPV), feline panleukopenia virus (FPV), minute virus of mice (MVM), 
Aleutian mink disease virus (ADV), and the human parvovirus B19, have been resolved 
during the past decade, the three-dimensional structure of the AAV capsid remained 
unknown (Agbandje et al., 1994; Agbandje-McKenna et al., 1998; Chang, Sgro, and 
Parrish, 1992; Chapman and Rossmann, 1993; Chipman et al., 1996; McKenna et al., 
1999; Strassheim et al., 1994; Tsao et al., 1991). Instead, alignments of these related 
parvoviruses with AAV had led to hypothetical models of the AAV capsid. Random and 
systematic mutagenesis approaches helped to identify functional sites on the capsid, 
including putative binding sites for the primary receptor HSPG, immunogenic epitopes and 
flexible loop regions at the capsid surface that accept the insertion of targeting ligands 
(Girod et al., 1999; Rabinowitz, Xiao, and Samulski, 1999; Wobus et al., 2000; Wu et al., 
2000). In 2002 the atomic structure of AAV has been determined to 3Å resolution by x-ray 
crystallography (Xie et al., 2002). 
Each viral capsid is composed of 60 subunits arranged with T=1 icosahedral 
symmetry (Xie et al., 2002). The three structural proteins VP1, VP2, and VP3, which share 
overlapping sequences and differ only at their N-termini (Figure 2), build the AAV capsid 
with a relative stoichiometry of about 1:1:20 (Kronenberg, Kleinschmidt, and Bottcher, 
2001). The central motif of each subunit is an anti-parallel ß-barrel which is highly 
conserved among parvoviruses. This β-barrel motif forms elongated smooth lumps at the 
inner surface of the capsid at the 2-fold symmetry axis (Kronenberg, Kleinschmidt, and 
Bottcher, 2001). Between the strands of the β-barrel core large loop insertions are found 
that share only low similarity among the parvovirus family. These loops comprise two-
thirds of the capsid structure and constitute the capsid surface features that interact with 
antibodies and cellular receptors. These surface features include a hollow cylinder at the 5-
fold axis of symmetry which is surrounded by a circular depression (canyon), and a 
depression spanning the 2-fold axis (dimple). The most prominent features of the capsid 
are the 3-fold-proximal peaks, which cluster around the 3-fold symmetry axis. The peaks 
are not derived from one capsid subunit protein but from the interaction of two adjacent 
subunits. Other interactions between loops of neighboring subunits are found at the 5-fold 
cylinder. Overall, the outside surface of AAV is positively charged with clusters of 
positive charges in the canyon, surrounding the 5-fold cylinder, and at the 3-fold symmetry 
axis. Regions of negative charges are mainly found at the top of the 5-fold cylinder and at 
the sides of the 2-fold dimple facing the 3-fold axes.  
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After resolution of the crystal structure of AAV important functions obtained from 
genetic data could be mapped to the structure. At the 3-fold-proximal peaks, in the valleys 
separating the three peaks of one 3-fold axis, clusters of positive charges are located, which 
are implicated in receptor binding. Although no definitive HSPG binding motif has been 
found on the capsid surface so far, mutational analyses have identified these locations 
being involved in binding to the primary receptor HSPG (Wu et al., 2000). Especially the 
basic amino acids (aa) R487, R585, and R588, which are at the side of the peak, seem to 
play a crucial role (Grifman et al., 2001; Wu et al., 2000; Xie et al., 2002). Interestingly, 
the separation between these clusters at the side of the peaks is 20 Å, consistent with 
binding neighboring disaccharides of the heparan sulfate moiety. The epitope of an AAV-
neutralizing antibody, A20, could also be mapped to the 3-fold spike region. It is situated 
in the valley between the peaks of one 3-fold axis (Wobus et al., 2000).  
 
 
1.3.  AAV Targeting Vectors 
 
The development of safe and efficient gene transfer vectors is crucial for the 
success of gene therapy. The adeno-associated virus is a promising vector for human 
somatic gene therapy, however, its broad tissue tropism, which is based on the widely 
spread of its primary receptor HSPG, is a disadvantage, if a tissue and organ-selective gene 
transfer after systemic application is disired. Although, AAV is known to infect diverse 
organs such as brain, liver, muscle, lung, retina and heart muscle (Carter and Samulski, 
2000), the vector has to be administed directly to reach clinically relevant gene expression 
(Monahan and Samulski, 2000; Tal, 2000). 
Therefore, increasing efforts have been made to target AAV-based vectors to 
specific receptors. So far, the most promising approach is the genetic modification of the 
viral capsid.  
The first successful demonstration that a genetic capsid modification can be used to 
retarget AAV was described by Girod et al. (1999). A sequence alignment of AAV and 
CPV identified six sites aa positions (261, 381, 447, 534, 573, 587) that were expected to 
be exposed on the surface of the virus capsid and to accept the insertion of a ligand without 
disrupting functions essential for the viral life cycle. At these positions, the sequence for 
the 14 amino-acid peptide L14 (QAGTFALRGDNPQG) was inserted into the capsid gene. 
The L14 peptide contains the RGD motif of the laminin fragment P1 and is the target for 
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several cellular integrin receptors, besides also serving as a viral receptor. An efficient 
transduction of B16F10 cells was observed using the AAV insertion mutant I-587 
expressing Rep or β–galactosidase (Girod et al, 1999). Grifman et al. (2001) inserted the 
Myc epitope and a CD13 (NGR receptor expressed on angiogenic vasculature and in many 
tumor cell lines) specific peptide with the sequence NGRAHA, identified by phage 
display, into positions 448 and 587. The insertion into 587 allowed a cell-specific targeting 
to different cell lines (KS1767 (Kaposi sarcoma) and RD (rhabdomyosarcoma)). 
Other approaches for efficient retargeting of AAV include the targeting by 
bispecific antibodies which mediate the interaction between virus and target cell and was 
first demonstrated by Bartlett et al (1999). The antibody used was generated by a chemical 
crosslink of the Fab arms of monoclonal antibodies against the αIIbβ3 integrin (AP-2 
antibody) and the intact AAV capsid (A20 antibody). The major ligand for αIIbβ3 is 
fibrinogen, which becomes internalized via endocytosis. Therefore, AAV targeted to this 
integrin was expected to become internalized via receptor-mediated endocytosis, similar to 
wild-type virus. This targeting vector transduced MO7e and DAMI cells, which are not 
permissive for wild-type AAV infection (70-fold above background). In contrast, a 90% 
reduction in AAV transduction was seen on cells negative for the targeting receptor. It 
remains to be determined whether this reduction was because of steric hindrance or some 
other mechanism. Another issue that remains to be resolved is the stability of the virus-
bispecific antibody complexes in vivo. 
 
Wu et al. (2000) inserted the receptor specific ligand of the HA epitope 
YPVDVPDYA into the N-terminal regions of VP1, VP2 and VP3 and the C-terminus of 
the cap ORF. They observed that the insertion of this and other epitopes at the N-termini of 
VP1 and VP3 and at the C-terminus of the cap ORF resulted in either no detectable 
particles (for VP3 and the cap ORF) or in a 2-3 log decrease of infectious and physical 
particle titers. In agreement with Yang et al. (1998) only the insertion at the N-terminus of 
VP2 was tolerated. Moreover exchanging the HA epitope by the serpin receptor ligand 
KFNKPFVFLI78 resulted in a 15-fold higher infection of the lung epithelial cell line IB3 
than by wild-type AAV.  
Studies demonstrating a successful in vivo retargeting of AAV vectors for other 
organs than the liver include the targeting of coronary endothelial cells (Muller et al. 2005) 
and human vascular endothelial cells (Nicklin et al. 2001, Shi and Bartlett 2003). To 
efficiently retarget AAV vectors, a better understanding of the infectious biology of AAV 
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will be required. This includes the virus-cell surface interactions, mechanism of uptake, 
endosomal processing and release, nuclear transport and mechanisms leading to gene 
expression.  
Another important issue is the identification of the optimal ligand or targeting 
receptor. Length and sequence of the ligand can be critical in insertion vectors, as the 
insertion of a peptide may result in profound alterations of the three dimensional capsid 
structure. This problem might be overcome by the combination of the insertion with one or 
more deletions or with the insertion of a sequence that is able to form its own secondary 
structure, for example, a loop closed by a cysteine bridge (Shi and Bartlett 2003; Wang et 
al. 2005).  
To identify new ligands, phage display is a valid approach. However, the ligand 
sequences are selected in an architectural context that is different from that of the final 
vector. This means that once inserted in the context of AAV, they could destabilize the 
capsid structure (resulting in low packaging efficiency) or lose their biological properties 
(resulting in low infectious titers). To overcome these difficulties the screening for new 
retargeting peptides to be inserted was done in the context of the AAV capsid itself, where 
a pool of randomized peptide sequences was inserted into the capsid sequence and the viral 
pool was then screened directly on target cells (Perabo et al. 2003).  
Perabo et al. applied the AAV library for selection of receptor-specific targeting 
mutants on different cell lines that were resistant to infection by wtAAV. Three mutants 
were obtained which transduced target cells with an up to 100-fold increased efficiency, in 
a receptor-specific manner and without interacting with the primary receptor for wtAAV. 
Extension of the library by randomizing the viral capsid by error prone PCR showed that 
mutants with improved phenotype can be obtained which are less efficiently neutralized by 
human antibodies and can, therefore, be used to generate novel vectors for the treatment of 
patients with pre-existing immunity to AAV (Perabo and Endell et al. 2006). 
Overall, the adeno-associated viruses are very promising gene transfer vehicles for 
the treatment of multiple diseases. The increasing interest in AAV as vector system and the 
rising amount of gene therapy trials which are currently under investigation argue for its 
potential as human gene therapy vector. Hurdles, however, still exist and have to be 
overcome, including specific and selective transduction of the target tissue and potential 
immune responses to the vector and/or the transgene.  
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2. Chapter I - Universal Targeting of AAV 
2.1. Introduction Chapter I 
The primary receptor of AAV is heparan sulphate proteoglycan (HSPG). Since 
HSPG is displayed on a wide variety of cells, AAV shows a broad tissue tropism. This 
limits cell-specific transduction of target tissue after systemic application and therefore 
targeting of AAV vectors plays an important role.  
In principle, two different strategies are possible to achieve a receptor targeting of 
AAV (Cosset and Russell, 1996):  
1. Indirect targeting: In contrast to wild type (Fig. 1A) the interaction between the viral 
vector and the target cell is mediated by an associated molecule (e.g. a bispecific 
antibody) which is bound to the viral surface and interacts with a specific cell surface 
molecule (Miller, 1996) (Fig. 1B).  
2. Direct targeting: The cell specific targeting of the vector is mediated by a ligand 
which is directly inserted into the viral capsid (Walter and Stein, 1996) (Fig. 1C).  
 
wild type tropism (A)
direct modification of viral capsid (C)
 cell virus interaction
by associated molecule (B)
 
 
 
tFigure 1: Possibilities of viral vector targeting (Büning et al. 2003).  
Viral vectors with wild type tropism (A) show a direct binding of structural capsid components to the cell 
surface receptor. In targeting vectors, the virus-cell interaction is mediated by a molecule associated with 
the capsid (indirect targeting, B) or by a ligand directly inserted into the capsid (direct targeting, C).  For indirect targeting it is not necessary to know the three-dimensional structure of 
he viral surface if high affinity viral surface binding molecules such as monoclonal 
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antibodies are available. For this strategy, the stability of the interaction of the virus with 
the intermediate molecule and the efficiency by which the complex is generated are rate 
limiting. In addition, the intermediate molecules must bind to cell-specific receptors which 
allow the uptake and correct intracellular processing of the virus.  
A combination of two important parameters is required for the successful 
generation of a targeting vector by direct modifications of the capsid: 
The first parameter is a good choice of the insertion site to ensure that packaging of 
the mutant virus remains efficient and the inserted ligand is exposed on the virus surface. 
Different strategies have been used for AAV to identify candidate positions for insertion of 
heterologous ligand: a) sequence alignment between AAV and other parvoviruses for 
which the X-ray crystal structure is known (Girod et al. 1999; Grifman et al. 2001); b) a 
systematic, insertional mutagenesis of the whole AAV capsid (Rabinowitz and Samulski, 
1999; Shi and Bartlett 2001; Wu et al. 2000). Since the X-ray crystal structure of AAV has 
been solved in 2002 (Xie et al. 2002), the selection of insertion sites can now be performed 
by educated guesses.  
The second important parameter is the choice of the targeting peptide. It is difficult 
to predict the secondary structure of the ligand inserted into the AAV capsid. Therefore, 
the ligand should be structure-independent and not too large to avoid the destabilization of 
the entire capsid. Finally, the ligand-receptor complex should be internalized in a way that 
allows an efficient transport of the virus and the release of the viral DNA into the cell 
nucleus. 
Direct and indirect targeting approaches and a combination thereof have been used 
to successfully retarget AAV (Bartlett et al. 1999; Girod et al. 1999; Grifman et al. 2001; 
Nicklin et al. 2001; Ried et al. 2002; Shi and Bartlett 2001; Wu et al. 2000; Yang et al. 
1998, Perabo et al. 2003, Muller et al. 2005, Stachler et al. 2006, Work et al. 2006). 
The basis of the current project was the work of Ried et al, who tried to create an 
universal targeting vector using a truncated 34 amino acid peptide, Z34C, from protein A 
of Staphylococcus aureus (Ried et al., 2002). Protein A recognizes and binds the Fc part of 
immunoglobulins (Ig), but not the variable region, which therefore remains free to bind the 
antigen. Z34C is derived from the protein A subunit B, which encompasses 56 amino acids 
and binds the Fc portion with a dissociation constant of about 10-50 nM (Sinha, Sengupta, 
and Ray, 1999). Z34C was inserted at position 587, previously described as retargeting site 
by Girod et al. (1999), into the AAV capsid (rAAV-587Z34C). This insertion allowed a 
functional expression of the IgG binding domain, as shown by binding studies using 
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various antibodies. Coupling 587Z34C AAV vector with different antibodies e.g. against 
CD29 (β1-integrin), CD117 (c-kit-receptor) or CXCR4 resulted in a specific, antibody 
mediated transduction of hematopoietic cell lines. No transduction could be detected 
without antibody, whereas the targeted infection was blocked with soluble protein A or 
with IgG molecules. In addition, no inhibition of transduction by the targeting vector was 
observed with heparin, demonstrating that the interaction of the 587Z34C mutants with the 
natural AAV receptor heparan sulphate proteoglycan (HSPG) was not essential for 
infection or transduction. Thus an universal targeting vector had been generated which 
allowed to exchange the respective tropism by simply exchanging the ligand coupled to the 
modified vector. 
However, vector titers (10-fold decrease in packaging efficiency) and transduction 
efficiency of the respective target cells were relatively low. The decreased packaging 
efficiency is most likely due to the size of the insertion (34 amino acids inserted into each 
of the 60 proteins of the AAV capsid) whereas the stability of the interaction between the 
antibody and coupling domain hampers from the fact that it is based only on non covalent 
interaction and could be one of the reasons for low transduction efficiency obtained. 
In 2001 Stubenrauch et al. described a specific coupling of an antibody fragment to 
the surface of polyoma VLPs via polyionic fusion peptides by complementary charge. 
Stability was increased by a disulfide bridge which covalently coupled the antibody 
fragment and the VLP. The antibody utilized in this study was the tumour-specific anti-
(Lewis Y) antibody fragment. This approach led to a retargeting of the modified polyoma 
particles towards antigen-presenting cells, thus demonstrating the basic concept for the 
development of a cell-type-specific, non-viral vector system. However, also in this study 
the transfection efficiencies were rather low, probably due to the degradation of polyoma 
VLP in lysosomes after cellular uptake (Stubenrauch et al. 2001).  
Kreppel et al. recently described a novel virus vector-targeting platform based on a 
unique combination of genetic and chemical vector particle modifications to overcome 
typical restrictions in virus vector targeting. (Kreppel et al. 2005). They genetically 
introduced cysteines into the HI loop of adenovirus, which is solvent-exposed position. 
The corresponding thiol groups were highly reactive, and they established procedures for 
controlled covalent coupling of protein and nonprotein ligands to them. After the coupling 
of apo-transferrin, the particles were efficiently targeted to the transferrin receptor 
pathway. Depending on the chemistry used, ligands could be coupled under the formation 
of thioether or disulfide bonds, the latter allowing for separation of ligand and particle after 
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cell entry into the endosome. Furthermore, this technology could be efficiently combined 
with vector shielding for true retargeting: after amino-PEGylation of the vector particles 
the genetically introduced thiols were still accessible for ligand coupling, and particles 
could be retargeted to the transferrin receptor. 
In the work described here, we tried to improve the concept of an universal AAV 
targeting vector by introducing a covalent linkeage between the modified AAV vector 
(carrying a coupling domain) and the ligand (which defines the tropism). Two different 
strategies were applied: a) specific coupling via polyionic fusion peptides combined with 
the introduction of cysteines for controlled covalent coupling and b) just the insertion of 
cysteine.  
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2.1. Results Chapter I 
Insertion of cysteine as reaction partner into the AAV capsid 
 
First, in analogy to Stubenrauch et al. (2001), the following strategy was performed 
to try to optimize the interaction between virus and ligand: a sequence of eight glutamic 
acids and one cysteine was inserted C-terminal of the amino acid position 587 into the 
AAV capsid utilizing standard cloning techniques. As counterpart the ligand (SIG peptide, 
see below) to be coupled was synthesized as fusion with a sequence of eight arginines and 
one cysteine. A first contact between ligand and vector capsid should be mediated by the 
polyionic sequences, followed by a covalent linkeage due to disulfide bridging by cysteine.  
The AAV mutant, AAV-Glu, was packaged in 293 cells and purified by iodiaxanol 
step gradient (details see Material and Methods). After purification AAV-Glu preparation 
was characterized. For genomic titer determination the Dot Blot method was used and 
capsid titer was determined by ELISA, utilizing an antibody (A20) which recognizes only 
intact AAV capsids. Both titers (4x108 genomic particles/µl and 1x109 capsid particles/µl, 
respectively) showed that the mutant could be packaged to titers comparable to wtAAV.  
To further purify the virus solution, purification by gel filtration and/or by anion 
exchange column were established and applied. Fractions of gel filtration were eluted with 
PBS and purified virus could be obtained from three fractions with high genomic and 
capsid titers (3x108 genomic particles/µl). Due to the inserted charged amino acids, an 
anion exchange chromatography (HiTrap ANX FF high sub, Amersham) could be 
performed. This was a first proof that the inserted negative charged amino acids are 
accessible on the capsid surface. The bound fractions were eluted with 1M NaCl. The high 
salt concentration was removed by gel filtration where 
necessary.  
 Figure 2:  
Oregon Green 488 maleimide 
(Molecular Probes) 
To analyse if the inserted cysteine is accessible 
for coupling, AAV-Glu was coupled to a thiol reactive 
dye, Oregon Green 488 maleimide (Figure 2).  
The coupling was conducted as described 
according to the protocol for thiol-reactive probes by 
Molecular Probes. Briefly, the thiol groups, introduced 
into the capsid of AAV-Glu, were reduced by 10-fold 
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molar excess of Tris(2-carboxyethyl) phosphine hydrochloride (TCEP). TCEP was chosen, 
because it does not interfere with the conjugation reaction to maleimides. The Oregon 
Green dye was added again in a 10-fold molar excess and incubated at room temperature 
for 2h. Excess dye was removed by dialysis. After dialysis the capsid titers were 
determined by A20-ELISA and same capsid particles (1x1010 capsid particles) were 
analyzed by SDS PAGE.  
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Figure 3: Conjugation of Oregon Green to AAV-Glu 
AAV-Glu and wtAAV were coupled to Oregon Green and dialyzed against PBS. Capsid titers were 
determined and same particles of all samples were applied to separation by SDS PAGE. Before blotting the 
SDS gel was analyzed by Phospho Imager using the blue channel (450nm) to detect Oregon Green. The gel 
was blotted to nylon membrane by semi-dry membrane transfer and the AAV capsid proteins were detected 
with B1 antibody. 
Lane 1: Marker; Lane 2,3: AAV-Glu +Oregon Green; Lane 4,5: AAV-A3 (HSPG knock out, Wu et al. 2000); 
Lane 6: wtAAV +Oregon Green; Lane 7: wtAAV w/o Oregon Green 
 
Phospho Imager allows the detection of Oregon Green dyes. When applying the 
SDS-Gel to the Phospho Imager for analysis, labelled bands were detectable (Figure 3A). 
The gel was then blotted and incubated with B1 antibody. B1 antibody is able to recognize 
unassembled viral capsid proteins (VP) 1, 2, and 3 of AAV (Bleker et al. 2005). In the 
Western Blot analysis (Figure 3B) only the VP3 could be detected for all vectors used. 
This is most probably due to the detection limit, since VP1, VP2 and VP3 are building up 
the AAV capsid in a 1:1:20 ratio (Rabinowitz et al. 1999) and already the VP3 signal was 
relatively weak. By comparing the bands detected in the Western Blot (Figure 3B) with the 
image taken with the Phospho Imager of the same SDS gel before blotting (Figure 3A), a 
labelled band for VP3 was detectable in the sample of AAV-Glu which had been coupled 
to Oregon Green. wtAAV, which was used as a control and had also been incubated with 
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Oregon Green, showed labelled bands in the Phospho Imager picture. However, none of 
these bands corresponded in size to the AAV VP proteins. 
These results show that the cysteine inserted in AAV-Glu is accessible for 
coupling. 
 
In the optimal situation, the interaction between the targeting vector and its target is 
only dictated by the inserted ligand (knock out for natural ligand:receptor interaction of the 
original virus). To determine the tropism of AAV-Glu, the transduction efficiency of 
AAV-Glu was determined in comparison to rAAV with unmodified capsid on HeLa 
(cervix carcinoma cell line) and SVEC (endothelial cell line). For this the cells were 
seeded into 24-well plates 24h before transduction. 4 different amounts of vectors were 
used (5x103, 1x104, 5x104 and 1x105 genomic particles per cell). Both vectors encoded the 
same transgene (enhanced green fluorescent protein). After 48h cells were harvested and 
analyzed for GFP expression by FACS analysis. 
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Coupling of rAAV to ligands via polyionic fusion peptides 
Conjugation to the SIG peptide 
In a first approach, the peptide SIGYPLP (SIG) was chosen as a coupling ligand. 
SIG was fished as an endothelial specific peptide by phage display by Nicklin et al (2000) 
and a SIGYPLP-modified AAV (AAV-SIG), with the SIG peptide inserted in position 587 
of the capsid, could be generated. AAV-SIG showed an efficient and selective tropism for 
endothelial vascular cells (EC) compared with control AAV vectors with wt capsid 
(Nicklin et al. 2001). Since AAV-SIG, was available as control mutant and had shown 
specific retargeting of endothelial cells, SIG was chosen in a first approach as coupling 
ligand. 
The peptide was synthesized by Dr. Arnold (Gene Center of LMU Munich) in a 
way that the SIG peptide was fused with eight arginines and one cysteine at the C-terminus 
to constitute the counterpart to the negatively charged sequence inserted in AAV-Glu. The 
polyionic SIG peptide was designed with and without a linker separating the peptide 
sequence and the polyionic part. 
AAV-Glu was coupled to the polyionic peptide with the same protocol as used for 
the Oregon Green conjugation reaction and the genomic titers were determined after 
coupling. One sample of a SIG peptide coupled to AAV-Glu was submitted to a further 
purification step by gel filtration and the genomic titer was determined subsequently.  
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As control, AAV-Glu without peptide was incubated under the same conditions to 
determine if the incubation conditions influenced the vector. SVEC cells were then 
transduced with genomic particles per cell of 5x104 and 1x105 for AAV-Glu and AAV-Glu 
coupled with the polyionic peptide with and without linker (Figure 5). 
AAV-Glu coupled to the peptide without linker did not show any enhancement in 
transduction efficiency compared to AAV-Glu (control; first two columns). The 
transduction efficiency could be doubled with AAV-Glu coupled to peptide with linker 
sequence and showed better transduction efficiency after purification by gel filtration. 
However, only transduction efficiencies of up to 4% (GFP expressing cells) could be 
detected with 5x104 genomic particles per cell. AAV-SIG carrying the same SIG sequence 
as an inserted peptide in 587 was able to transduce the same cells up to 50% under the 
same conditions (example see Figure 6).  
To determine if the high transduction efficiency on SVEC observed for AAV-SIG 
was mediated by the inserted peptide, competition experiments utilizing the SIG peptide 
were performed. For this the AAV-SIG was preincubated with the SIG peptide, the same 
which was used for the coupling, in 10-fold molar exess and then utilized to transduce 
SVEC.  
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restingly, incubation with the peptide had no influence on the transduction 
for AAV-SIG. Although Nicklin et al. had used heparin to show that AAV-SIG 
Chapter I - Universal Targeting of AAV 23
transduced HUVECs independently of AAVs primary receptor, they never did a peptide 
competition. Because the receptor for the SIG peptide is still unknown and it was not 
possible to block AAV-SIG transduction of SVEC by soluble SIG peptide, it was decided 
to utilize the tumour-specific B3 (Lewis Y) antibody as ligand which was already used by 
Stubenrauch et al. for the same coupling reaction to establish this coupling procedure with 
AAV within this project. 
Conjugation to the B3 (Lewis) antibody 
B3 (Lewis Y) antibody specifically recognizes tumour cells presenting the antigen 
Lewis Y, a sugar residue found on breast tumours and epidermoid tumour cells 
(Brinkmann et al. 1991). As already stated, this was the same ligand Stubenrauch and 
colleagues used for their approach and was kindly provided by Hauke Lilie (University of 
Halle).  
The protocol was varied by addition of Dithiopyridine (DTP), which facilitates the 
binding of small amounts of thiol groups. The B3-antibody, fused to eight arginines and 
one cysteine, was activated by incubation with DTP which should help to enhance the 
binding to the thiol group inserted in the viral capsid (for detailed protocol see Material 
and Methods). After coupling the solution was submitted to gel filtration to eliminate non 
reacted free B3-antibody, which might interfere with the transduction experiment. 
Genomic titers were determined by Dot Blot and MCF-7 cells, a breast carcinoma cell line, 
were transduced with coupled and uncoupled AAV-Glu and rAAV/GFP (with unmodified 
capsid) as control.  
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bation with DTP (for detailed conjugation protocol see Material and Methods). MCF-7 cells 
 24 well plates and were transduced 24h later with genomic particles per cell of 1x104, 
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For both coupling approaches, increasing transduction efficiencies were observed 
with increasing amounts of vectors with the samples containing AAV-Glu after coupling to 
B3-antibody (Figure 7). However, the transduction efficiency obtained was only 
comparable with transduction effiency reached by the uncoupled AAV-Glu. In addition, 
rAAV with wild type capsid showed the best transduction efficiency. However, 
transduction efficiency reached in general was very low, only up to 6%. In contrast, 
Stubenrauch et al. could detect a 5-fold increase in transduction efficiency of their β–
galactosidase encoding virus like particles (VLPs) conjugated to B3-antibody. 
(Stubenrauch et al. 2001)  
A new coupling attempt was analyzed by SDS PAGE, followed by silver staining 
(instead of transduction experiments) to analyse if at least coupled B3-antibody was 
detectable. To determine the amounts of antibody necessary to detect a signal by silver 
staining, unbound B3-antibody was also analysed by SDS PAGE in addition. With respect 
to the coupling approach, AAV-Glu and B3-antibody were conjugated as described before 
and submitted to gel filtration to separate the coupled virions from free B3-antibody. The 
coupled virion proteins were separated in a SDS-PAGE under reducing conditions. 
Subsequently the gel was silver stained (Figure 8). For the B3-antibody a band at 14kDa 
was expected, as this is the antibody size. For the conjugated AAV-Glu-B3 complex, the 
VP proteins should be detectable and in addition a signal at 14kDa for the B3-antibody 
separated by the reducing conditions in the gel.  
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 was conjugated to AAV-Glu using the DTP protocol as described above and then separated 
E under reducing conditions. Proteins were detected by silver staining of the gel. 
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Amounts of 100ng as well as 10ng of B3-antibody were still detectable in the silver 
stained SDS gel. However, beyond this amount no signal was detectable. For the coupled 
AAV-Glu 90, 180, 270, and 320 ng had been used, respectively. In case of 3.2x1010 AAV 
particles used and assuming that the antibody is bound to all 60 subunits, a total of 45ng of 
antibody would be bound to the 3.2x1010 AAV particles. Taking into account that only part 
of the used antibody would have been coupled to AAV-Glu, at least 25% need to be 
coupled to be detectable. Lower amounts would not be possible to detect by silver staining 
as might be the case. 
Although we could prove that both, the negative charged amino acids and the 
cysteine of the inserted peptide are accessible at the AAV capsid, we could not 
demonstrate that an efficient coupling of peptides to AAV-Glu by disulfide bridging via 
polyionic fusion peptides is possible.  
 
Coupling by maleimide reaction 
 
Since coupling of the inserted cysteines with a maleimide group had been proven 
by conjugation of the Oregon Green to AAV-Glu before, we decided to use the same 
reaction to couple a ligand to the AAV capsid. 
To perform this reaction another coupling system had to be used, but still the thiol 
group of the inserted cysteine in AAV capsid could be utilized, but this time with a 
maleimide group as reaction partner. Maleimide and thiol form a stable thioether under 
reducing conditions (Figure 9).  
 
Figure 9: Thioether formation of thiol groups with maleimide (Molecular 
Probes)  
 
For this approach a cooperation was started with Florian Kreppel (University of 
Ulm), who applied this coupling system to Adenovirus. Kreppel et al. (2005) were able to 
introduce a specific chemical reactivity by cysteine at defined positions in the viral capsid 
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surface of Ad5. This chemical reactivity was, after production of the viral vector from 
conventional producer cells, used to chemically couple ligands for targeting. For this, a 
short cysteine containing motif LIGGGCGGGID was inserted into the solvent-exposed 
fiber HI loop of Ad5. They could show that NANOGOLD monomaleimide particles and 
monofunctional maleimide-bearing 5k-polyethyleneglycol molecules (5k-PEG-Mal) could 
be covalently linked to the genetically introduced cysteines. The coupling was detectable 
in SDS PAGE under reducing conditions and Western Blot. By coupling apo-transferrin 
ligand, with an introduced thiol-reactive maleimide group, to the Ad-Cys vector, they 
could show increased transduction efficiency in CAR-deficient K562 cells, which could 
not be transduced by Ad-Cys alone.  
Crucial for the coupling was the chemical reactivity of the genetically introduced 
thiol groups on the surface of the vector particles. Thiol groups were activated by reducing 
agents dithiothreitol (DTT) or Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) and 
Kreppel et al. showed that the reducing agents had no influence on the infectivity of the 
vector particles. To keep the thiol groups activated the vectors were kept under argon 
atmosphere to prevent oxidizing events. Once the ligands were coupled to the vector, argon 
atmosphere was not needed anymore and the coupled vectors could be stored under 
conventional conditions.  
To apply this approach to AAV, a new vector was created by insertion of the 
peptide LIGGGCGGGID into the 587 site and AAV-Cys was packaged according to the 
AAV production protocol using oxygen free buffers and was then reduced with TCEP and 
kept under argon atmosphere (this last part was carried out in Ulm).  
 
 
 
 
 
 
 
VP1 ► 
 
VP2 ► 
 
 
VP3 ►  
Figure 10: Conjugation of PEG-Mal (5k) to AAV-Cys 
Thiol groups AAV-Cys were reduced by TCEP and then conjugated to PEG-Mal in oxygen free 
atmosphere. Conjugated protein particles were separated by reducing SDS and then transferred to a nylon 
membrane and AAV VP proteins were detected by B1 antibody in Western Blot. Conjugation and analysis 
in Western Blot was kindly carried out and the results provided by Florian Kreppel, University of Ulm.  
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5k-PEG-Mal was coupled to the reduced AAV-Cys and submitted to SDS PAGE 
under reducing conditions and AAV capsid protein VP1, VP2, and VP3 were detected by 
B1 antibody in Western Blot. For efficient coupling a shift should be seen in the VP 
proteins, where the additional cysteines were introduced.  
No shift in the VP capsid proteins could be seen after coupling of 5k-PEG-Mal to 
AAV-Cys. In contrast a shift was seen when coupling 5k-PEG-Mal to Ad-Cys under the 
same conditions (Kreppel et al. 2005). 
 
Evaluation of new substitution sites for cysteine residues 
Since the insertion of cysteine with a short linker motif into 587 did not show 
coupling efficiency with PEG-Mal in Western Blot analysis, new insertion sites were 
determined. The reason for this was the hypothesis, that the cysteine within the linker used 
inserted in 587 was not accessible for the coupling reaction. For this reason, we generated 
6 different mutants, in which on exposed sites (according to the crystal structure of Xie and 
colleagues) an one amino acid substitution towards Cysteine was performed. The following 
residues were selected for substitution with cysteine: N587C, S452C, G453C, A667C, 
G265C and S384C. In all cases it was considered that only smaller amino acids and those 
which play a minor role in structure definition like serine or glycine were exchanged. All 
the mutants were cloned by PCR cloning, could be successfully packaged with GFP as 
transgene and purified by Iodixanol step density gradient to genomic (determined by Light 
Cycler PCR) and capsid titers, which were comparable to the titers obtained for wtAAV 
(data not shown). The new obtained mutants are currently being tested for efficient 
conjugation and retargeting with apo-transferrin in cooperation with Florian Kreppel 
(University of Ulm). 
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2.3. Discussion Chapter I 
The broad tissue tropism of AAV2, mediated by its primary receptor heparan 
sulphate proteoglycan (HSPG), represents a disadvantage for in vivo gene therapy, because 
after systemic application, viral vector particles are sequestered by a wide variety of HSPG 
displaying cells and only few particles will reach organs other than liver and spleen.. 
Strategies to alter the tropism include the insertion of peptides into the AAV capsid, 
creating targeting mutants useful for one specific receptor-ligand interaction. Universal 
targeting approaches seek to redirect rAAV binding to specific cell surface receptors by 
simple coupling of different ligands to its capsid. Bartlett et al. (1999) demonstrated that 
bispecific antibodies, mediating interaction between AAV vector and a specific cell surface 
receptor, can redirect the tropism to megakaryocyte cell lines, usually non-permissive for 
AAV2. Although they were able to overcome the block to transduction of non-permissive 
cell lines, the level of vector-mediated gene expression was still very low. Ried et al. 
(2002) inserted a minimized domain of protein A into position 587 to couple various 
antibodies binding to specific cell surface receptors to the AAV capsid and demonstrated 
that the infection in target cells was specifically antibody mediated. However also in this 
case, the transduction efficiency was fairly low. Based on the hypothesis, that the low 
transduction efficiency observed by Bartlett et al and Ried et al. is maybe caused by the 
instability of the ligand-capsid interaction, we sought to generate an universal AAV 
targeting vector by coupling the ligand via a disulfide bridge to the modified AAV capsid. 
AAV tolerates insertion of polyionic sequence and cysteine into the 
capsid structure  
Different insertion strategies were tested to incorporate cysteine into the AAV 
capsid. In a first approach a polyionic peptide (eight glutamic acids and one cysteine) was 
inserted into position 587. The capsid tolerated the insertion and the vector could be 
purified to high titers by anion exchange chromatography due to the inserted negatively 
charged glutamic acids. This negative charge is also responsible for the inability to 
transduce HeLa or SVEC, which display as most adherent cells, the negatively charged 
HSPG on their cell surface. HSPG naturally serves as primary receptor of AAV. Based on 
this, AAV-Glu can be described as a knock-out mutant with ablation of the natural AAV 
tropism. This is an ideal situation for the generation of targeting vectors.   
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AAV-Glu can be conjugated to Oregon Green dye by thiol maleimide 
reaction 
To proof that the conjugation to a ligand is mediated by the inserted cysteine, 
AAV-Glu was coupled to Oregon Green Dye. The maleimide group of Oregon Green had 
to react with the thiol group of the cysteine introduced into the AAV capsid in AAV-Glu. 
Only in the AAV-Glu sample which underwent the conjugation reaction with Oregon 
Green bands were detectable in Phospho Imager after SDS-PAGE which corresponded to 
the VP3 protein in Western Blot analysis of the very same gel (Figure 3). WtAAV, which 
were also submitted to the coupling reaction, showed no labelled protein, which 
corresponded in size to one of the capsid proteins. 
These results proof that the cysteine is accessible for coupling (in addition to the 
negatively charged glutamic acids) (Figure 3 Conjugation of AAV-Glu to Oregon Green).  
Conjugation of AAV-Glu did not result in efficient transduction of target 
cells 
For conjugation of a target peptide to AAV-Glu, the SIG peptide was chosen in a 
first approach, which consists of seven amino acids (SIGYPLP) and was fished in phage 
display as an endothelial specific peptide (Nicklin et al. 2000). The peptide had been 
incorporated into the AAV capsid into the 587 position by Nicklin et al. (2001) and the 
mutant AAV-SIG was able to successfully retarget to Human Umbilical Vein Endothelial 
cells (HUVEC). Specificity of the vector was proven by heparin competition studies on 
HUVEC, showing that rAAV-SIG is able to transduce these cells independent on AAVs 
natural primary receptor HSPG. Furthermore, the selective specificity of the binding was 
shown by infection studies using different non-endothelial cell lines such as HepG2 
(Nicklin et al. 2001). 
The SIG-peptide was designed with and without a linker region separating the 
seven amino acids of the targeting sequence and the polyionic coupling sequence. The 
linker should guarantee a more flexible structure. SIG-peptide was coupled to AAV-Glu 
according to the protocol used by Stubenrauch et al. (2001) to couple polyoma VP protein 
to B3 antibody, also using polyionic sequences. When AAV-Glu was coupled to the SIG 
peptide with linker, the transduction efficiency could be doubled reaching 4% GFP 
expression compared to AAV-Glu alone. However AAV-SIG, containing the respective 
peptide inserted in 587 reached transduction efficiencies of about 50%.  
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To analyse if the high transduction efficiency of AAV-SIG on SVEC is mediated 
by the inserted peptide, competition studies were performed. Here no reduction in the 
transduction efficiency could be seen. Although Nicklin et al. (2001) did a detailed 
analysis of the intracellular interaction of AAV-SIG in endothelial cells utilizing different 
chemical substances, such as bafilomycin A (inhibitor of the vascuolar H+-ATPase 
responsible for acidification of endosomal vehicles), no peptide competition experiments 
were done. Therefore, it can not be excluded that AAV-SIG is utilizing additional 
ligand:receptor interaction for the transduction of SVEC.  
A better characterized ligand receptor system was then chosen, using the B3 
(Lewis) antibody for conjugation and MCF-7 as target cell line. The antibody was kindly 
provided by Hauke Lilie from the University of Halle, whose colleagues were successful in 
conjugating B3 antibody to the polyoma virus VP1 protein. Using a protocol with 
Dithiopyridine (DTP) to activate thiol groups of the ligand, the B3 antibody was 
conjugated to AAV-Glu and the transduction efficiency was tested on MCF-7 cells. 
Conjugated AAV-Glu did not show better transduction efficiency than AAV-Glu alone. 
Conjugated AAV-Glu was then biochemically analysed by performing SDS-PAGE 
and silver staining to also detect small amounts of antibody. In addition different amounts 
of B3 antibody were also submitted to SDS PAGE and silver staining to determine what 
amounts of antibody are still detectable in the gel. 10ng or more of B3 antibody could be 
easily detected in a silver stained gel. Smaller amounts were not visible anymore. In the 
conjugated AAV-Glu sample no bands for the antibody were detectable (Figure 8). 
Although more than 10ng of B3 antibody were used for conjugation of AAV-Glu in the 
sample analysed, unconjugated antibody had been separated by gel filtration. Since it is 
very unlikely that all available antibodies were coupled to the vector, the failure to detect 
B3 antibody in the conjugated AAV-Glu sample is explainable by detection limit. 
However, this result showed that this method can not be used for our analysis. In contrast, 
Stubenrauch et al. could show conjugated B3 antibody in Coomassie stained SDS gels. 
However, they were able to analyse high amounts of VP1 protein and antibody. 
Taken together, we could show that AAV-Glu, carrying an insertion of eight 
glutamic acids and one cysteine, can be generated and purified to high titers. AAV-Glu is a 
promising basis for a targeting vector, since it is ablated of AAVs natural receptor usage. 
In addition, the inserted amino acids are accessible, since purification could be performed 
making use of the inserted negatively charges glutamic acids and Oregon Green maleimide 
dye could be coupled to the vector via the inserted cysteine (no reaction with wtAAV). 
Chapter I - Universal Targeting of AAV 31
However, neither with the SIG peptide nor with the B3 antibody fragment an enhanced 
transduction of the respective target cell by the new targeting vector could be detected in 
comparison to the controls. It can not be excluded that the test system (cell lines, peptide 
ligands) were not suitable for this approach and we therefore failed to proof the success of 
this targeting approach. However, also other options have to be taken into accounts as for 
example repulsion of AAV-Glu by the negatively charged HSPG molecules on the cell 
surface on the target cell if the inserted 480 negative charges are not completely covered 
by the coupled ligand. 
 
Conjugation of AAV-Cys to ligands by maleimide reaction 
For the AAV-Cys vector, cysteine was inserted into position 587 flanked by spacer 
amino acids (LIGGGCGGGID (AAV-Cys)). This sequence was previously successfully 
inserted into the solvent-exposed fiber HI loop of Ad5 by Kreppel and colleagues, who 
conjugated apo-transferrin to the cysteine containing Ad mutant (2005). The cysteine 
modified AAV-Cys could be packaged and purified to high titers, but was not able to 
transduce HeLa cells (data not shown). This might be due to the insertion, which might 
interfere with the arginines important for HSPG binding in positions 585 and 588 (Opie et 
al. 2003; Kern et al. 2003) and therefore ablate the natural HSPG binding. That such a 
mechanism can indeed take place, was shown within this thesis (Endell, Goldnau, Perabo, 
White et al. in revision and Chapter III). 
 
For the coupling a new ligand system was chosen, this time using a thioether 
reaction for conjugation. These experiments were performed in cooperation with Florian 
Kreppel at the University of Ulm, who established this coupling system for adenoviral 
vectors (Kreppel et al. 2005). The expected shift in the VP proteins of AAV-Cys could not 
be detected in Western Blot after conjugation to 5k-PEG-Mal ligand, a PEG molecule 
containing a maleimide group for the thioether reaction, indicating that the conjugation had 
not been successful. Since the reaction conditions had already been optimized by Florian 
Kreppel during his experiments with Ad5 (Kreppel et al. 2005), the failure of AAV-Cys to 
become coupled to PEG-Mal is most likely due to an inaccessibility of the Cys, when 
inserted within the LIGGGCGGGID sequences in 587. For the studies with Ad this 
sequences was inserted to the fiber HI-loop, protruding from the viral structure, now it is 
inserted within the three dimensional structure of a viral capsid. Based on this assumption, 
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a new insertion strategy was applied, this time only exchanging amino acids at exposed site 
within the AAV capsid. Only small and uncharged amino acids were exchanged, to avoid 
major changes in the capsid structure. Six amino acids were selected, which are displayed 
on the capsid surface according to the crystal structure of AAV (Xie et al. 2002). Amino 
acids were exchanged for cysteine obtaining the following Cys-mutants G265C, S384C, 
S452C, G453C, N587C, and A667C. All mutants could be packaged and are currently 
analysed in cooperation with Florian Kreppel (University of Ulm). The mutants are 
expected to be conjugated to ligands like 5k-PEG-Mal and apo-transferrin.  
Since this approach can integrate clinically diverse molecules as ligands, it may be 
used for clinical gene therapy and, potentially, also for vaccination in the future. 
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3. Chapter II - Development of an AAV based anti-idiotypic 
vaccine 
3.1. Introduction Chapter II 
IgE as Therapeutic Target in Allergic Diseases 
A promising indication for the treatment with anti-idiotypic vaccines are allergic 
disorders. Allergic diseases, including allergic asthma, are hypersensitivity reactions 
initiated by immunologic mechanisms. They are usually mediated by Immunoglobulin E 
(IgE) antibodies, which trigger an inflammation characterized by increased production of 
TH2-type cytokines at mucosal surfaces.  
The physiological role of IgE is to protect against helminthic parasites. In allergic 
reactions IgE triggers a defensive immune response against innocuous antigens by antigen 
binding to IgE antibodies which are bound to the high affinity receptor FcεRI on mast 
cells. The reactions vary from irritating sniffles of hay fever to life-threatening circulatory 
collapse and systemic anaphylaxis. In the body IgE is found mostly bound to its high 
affinity receptor FcεRI, whereas other antibodies are located mostly in body fluids. The 
FcεRI binds IgE to mast cells, basophils and activated eosinophils. When the cell-bound 
IgE antibody is cross-linked by a specific antigen, FcεRI mediates an activating signal. 
With high concentration of IgE, the receptor is also upregulated and thus enhancing the 
sensitivity. On activation, mast cells synthesize and release, besides histamine, other 
chemokines, lipid mediators such as leukotrienes and platelet-activating factor (PAF), and 
additional cytokines such as IL-4 and IL-13 which perpetuate the TH2 response. 
The inflammatory response after IgE-mediated mast-cell activation occurs as an 
immediate reaction, starting within seconds, and a late reaction, which takes up to 8 – 12 
hours to develop. The immediate reaction is due to the activity of histamine and other 
preformed or rapidly synthesized mediators that cause a rapid increase in vascular 
permeability and the contraction of smooth muscle. The late-phase reaction is 
characterized by the TH2 reaction and a more sustained inflammation process.  
Allergy can be treated by inhibiting either IgE production by desensitization or the 
effector pathways activated by cross-linking of cell-surface IgE. In desensitization the aim 
is to shift the antibody response away from one dominated by IgE toward one dominated 
by IgG, the latter can bind to the allergen and thus prevent it from activating IgE-mediated 
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effector pathways. Patients are injected with escalating doses of allergen, starting with tiny 
amounts. This injection schedule gradually diverts the IgE-dominated response, driven by 
TH2 cells, to one driven by TH1 cells, with the consequence of down regulation of IgE 
production. A potential complication of the desensitization approach is the risk of inducing 
IgE-mediated allergic responses. 
Another strategy that shows promise in experimental models of allergy is the use of 
oligodeoxynucleotides rich in unmethylated cytosine guanine dinucleotides (CpG) as 
adjuvant for desensitization regimes. These oligonucleotides mimic bacterial DNA 
sequences known as CpG motifs and strongly promote TH1 responses via Toll-like receptor 
9 (TLR9). The direct conjugation of CpG oligonucleotides to allergen may be a potent 
stimulus to cause allergen desensitization while minimizing potential CpG side effects. 
(Krieg and Walfield et al. 2002).  
Active immunization approaches, which have also not reached clinical trials yet, 
include vaccination with synthetic IgE peptide (Wang et al. 2003), where Wang and 
colleagues chose a peptide, which targets the binding site on IgE for the high affinity 
receptor FcεRI. The chosen peptide was immunopotentiated by linkage to a combinatorial 
T helper epitope derived from measles virus, UBITh®A, to provoke an immune response 
and allow active immunization. A polyclonal antibody response could be generated in dogs 
and these antibodies blocked binding to the high affinity receptor FcεRI, and were 
sufficiently immunogenic to evoke functional anti-dog IgE immune responses in dog.  
Other approaches try to interrupt the involved Interleukin pathways, such as IL-13, 
IL-4 or IL-5. Clinical trials show rather limited beneficial effects for interrupting the IL-4 
or the IL-5 pathway. Also the redundancy between some of the activities of these cytokines 
might make this approach difficult to implement in practice (Jonkers et al. 2005).  
Another target for therapeutic intervention might be the high affinity IgE receptor 
FcεRI itself. An effective competitor for IgE at this receptor could prevent the binding of 
IgE to the surfaces of mast cells, basophils and eosinophils. Candidate competitors include 
modified IgE Fc constructs that bind to the receptor, but lack variable regions and thus 
cannot bind antigen, or humanized anti-IgE monoclonal antibodies, which bind to the Fc 
part of IgE and block its binding to the receptor. A recombinant humanized monoclonal 
antibody is Omalizumab (Xolair®). Xolair® has been on the US market for a couple of 
years now and has been approved for the German market in November 2005. Xolair® is 
indicated for patients with moderate to severe forms of allergic asthma, who already 
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depend on the treatment with inhaled corticosteroids (ICS) and β-antagonists and show 
raised serum IgE levels. 
Although Omalizumab already works well in practise, the treatment with 
monoclonal antibodies bears several disadvantages, since it represents a passive 
immunization. It has to be applied in short time intervals during the treatment according to 
the severity of the disorder and the IgE level has to be closely monitored. If injections are 
stopped, the allergic reactions will reoccur after antibody serum levels are decreased again. 
The patients depend on a life long treatment. Furthermore, the risk of development of anti-
idiotypic antibodies (anti-Omalizumab), which could lead to the loss of efficacy and 
resistance against the therapy, exists. 
Anti-idiotypic vaccines are already in use for the treatment of autoimmune diseases 
or cancer. These anti-idiotypic antibodies raise antibodies directed against antigens that 
mediate e.g. autoimmune disease or are expressed by tumour cells and are a major 
improvement of passive immunization therapies. Furthermore anti-idiotypic antibodies 
induce a polyclonal antibody response against the target antigen, minimizing the risk of 
development of therapy resistance, while for passive immunotherapy monoclonal 
antibodies are used. A disadvantage of anti-idiotypic antibodies as vaccines is that induced 
antibody titers are often lower due to the low immunogenicity of antibodies. 
The combination of the advantages of an anti-idiotypic antibody with a suitable 
immunogen eliciting a sufficient immune response would represent a new approach with 
great benefit for the patients suffering from severe allergic disorders. 
Viruses bear the necessary polymeric structure which is recognized by the host as 
immunogenic and can thereby break B-cell tolerance against self-antigens such as IgE 
(Abbas and Lichtman Basic Immunology 2004). The Adeno-Associated Virus (AAV) is 
known for its low immunogenicity showing minor T-cell response, but is still able to elicit 
immune responses on the B-cell level, corroborated by the fact that over 50 to 96% of 
human beings show antibodies against different AAV serotypes such as AAV type 2 
(Chirmule et al. 1999). 
 
If an AAV mutant, resembling an anti-idiotypic sequence to e.g. Omalizumab and, 
therefore, resembling the FcεRI binding region of IgE, is selected who is able to stimulate 
the immune system in a way that suppresses the level of its own IgE by generating 
antibodies against the FcεRI binding region of IgE, it can be applied as a vaccine for active 
immunization and a new treatment is only needed when anti-IgE antibody titers are 
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decreasing. The treatment possibly has to be refreshed every few years then, in contrast to 
treatments with monoclonal antibodies every few weeks. 
 
Perabo et al. developed a combinatorial approach based on an AAV virus library 
for generation of efficient and receptor-specific targeting vectors with desired cell tropism 
(Perabo et al. 2003). The AAV library, which was in this project utilized for the selection 
of AAV capsid mutants, able to elicit an anti-IgE immune response, consists of 
approximately 4x106 capsid-modified viral particles carrying random insertions of 7 amino 
acids at position 587 of the AAV capsid protein. The choice of a 7-mer was empirical and 
dictated by the need to insert a sequence long enough to generate an acceptable amount of 
diversity, but without impairing the capsid stability. Typical B-cell epitopes are 5 or 6 
amino acids in length (Abbas and Lichtman Basic Immunology 2004), this should be 
sufficient to induce B-cell responses against the inserted peptide sequence when used as 
vaccine.  
In this study the AAV library is applied to a selection procedure using antibodies 
coated to a solid phase. By this AAV mutants can be selected which bind specifically to 
the desired idiotype of the selection antibody and which, therefore, resemble the epitope of 
the antibody target. Since antibodies are available against a great number of targets, it will 
allow selection of specific mutants resembling a wide variety of target epitopes.  
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3.2. Results Chapter II 
Coupling of geno- and phenotype 
The AAV library contains a pool of AAV capsid mutants, which differ from each 
other by the random insertion of seven amino acids at position 587 in the VP3 region of all 
60 capsid proteins. When packaging the AAV library, a pool of plasmids coding for the 
mutant capsid proteins, the viral replication proteins Rep, and harbouring the inverted 
terminal repeats (ITRs), is introduced into 293 cells by transfection (Figure 1). 
  
Figure 1: Packaging of the AAV library
Briefly, the DNA library plasmids are transfected into 293 cells together with adenoviral 
helperplasmid pXX6-80 at a molar ratio of 2:1. After 48h cells are lysed and the viral progeny is 
purified by Iodixanol density gradient. 
Transfection of high DNA concentration of a given plasmid results in the 
introduction of multiple copies per cell, which can replicate and express AAV capsid 
proteins with different inserted 7mere sequences. 60 capsid proteins build up a mosaic 
capsid encoding one AAV genome being randomly chosen. Therefore, many if not most of 
the AAV particles will contain a vector genome which is not related to any of its 60 capsid 
proteins, geno- and phenotype of this mosaic viruses are uncoupled. As later AAV 
selection is based on the AAV phenotype (the capsid variant) and because the sequence 
information for the selected AAV variant can only be gained from the respective AAV 
genome, a coupling of geno- and phenotype is indispensable. Therefore, the production of 
homogenous library mutants can not be guaranteed by simply packaging the AAV library 
using the transfection protocol described above. Based on this, it becomes clear that a 
coupling step had to be introduced which resulted in a pool of viral mutants each 
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consisting of a viral capsid displaying only one kind of peptide insertion and containing 
only the respective viral genome. 
 
Blocking Conditions 
For the selection of AAV library mutants on antibodies, the antibodies have to be 
coated to wells to allow a solid phase selection procedure. To avoid unspecific binding of 
the AAV library to the plastic material, the blocking conditions were optimized. Three 
different blocking reagents, Milk Powder (1% Milk Powder/PBS/1% Tween20), BSA (3% 
BSA/PBS/5% Saccharose/0.05% Tween20), and Casein (1% Casein/PBS/1% Tween20), 
were tested.  
Wells were coated with A20 antibody, which recognizes intact AAV capsids, or 
PBS, respectively, and then incubated with the above mentioned blocking buffers. As 
control, PBS was applied instead of a blocking buffer. Wells were then incubated with 
rAAV/GFP with 1x103 genomic particles per cell (GPC) in blocking buffer or PBS, 
respectively, and after washing HeLa cells were seeded on top and cultured for 48h. GFP 
expression in AAV transduced cells was determined by FACS analysis. The experiment 
was repeated at least three times. High transduction efficiency should be observable in 
wells coated with A20, where the binding of virions to the well was mediated by A20. In 
wells "coated" with PBS no or only low transduction efficiency should be detectable since 
AAV binding to the well was impeded by the blocking reagent.  
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As expected, in wells coated with A20, a transduction efficiency of 80 to 100% was 
achieved in all cases, Casein blocking showed the least expression with 80%. Here the 
blocking buffer might have interfered with the binding of AAV to A20 leading to a lower 
GFP expression. Comparing all wells "coated" with PBS, followed by blocking with three 
different blocking reagents and subsequent AAV incubation, GFP expression was still high 
(about 40%) in wells blocked with BSA, suggesting that blocking of the plastic material 
was insufficient in this case allowing for AAV binding to the plastic and subsequent uptake 
by HeLa. In contrast, blocking of the wells with Milk Powder or Casein was complete as 
AAV bound to the plastic being subsequently taken up by HeLa only led to GFP 
expression of 2%. In conclusion Milk Powder seems to be the most suited blocking reagent 
to avoid unspecific binding of virions to the well material, but allowed specific binding of 
AAV to the coated antibody.  
Therefore, in all following experiments a 10% solution of Milk 
Powder/PBS/1%Tween 20 was used as blocking reagent. 
 
Coupling of geno- and phenotype:   A) unspecific uptake 
Prior to AAV selection on antibodies a method was to be developed to ensure the 
production of homogenous library mutants and to eliminate the problem of not matching 
geno- and phenotype within one mutant. To achieve replication of only one mutant per 
cell, coupling through cell transduction with comparatively low virus concentrations was 
tested. In doing so, two different methods to get the AAV particles into the cell were 
compared: A) unspecific uptake, and B) receptor-mediated uptake or simple virus 
infection. The latter method bears the risk that an undesired selection of infectious virus 
takes place which could lead to a loss of target (antibody-) specific but non-infectious 
AAV variants. 
All viruses must have evolved ways of entering cells to initiate replication and 
progeny production. In case of AAV the virus enters the host cell through clathrin-
mediated endocytosis (Bartlett et al. 2000). The internalization is facilitated by its primary 
receptor heparan sulfate proteoglycan (HSPG) and the secondary receptors, of which three 
have been postulated, the fibroblast growth factor receptor I (FGFR), the αvβ5 integrin and 
recently the hepatocyte growth factor receptor (HGFR) (Qing et al. 1999; Summerford et al. 
1999; Kashiwakura et al. 2005). Following internalization into the early endosome, the virus 
encounters a weakly acidic environment which is necessary for endosomal escape into the 
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cytosol. AAV then accumulates perinuclearly and viral uncoating takes place before or 
during nuclear entry (Lux et al. 2005). 
Other endocytotic pathways include caveolae, macropinocytosis or non-clathrin, 
non-caveolae pathways. Macropinocytosis is generally considered to be a nonspecific 
mechanism for internalization, in that it is not reliant on ligand binding to a specific 
receptor. Instead, formation of endocytotic vesicles occurs as a response to cell 
stimulation. Such virus mediated signaling has been shown for adenovirus, where integrin-
dependent virus binding activates macropinocytosis. Cells, which use macropinocytosis as 
a major route, are e.g. antigen-presenting cells like dendritic cells (DCs) and in this case 
not even cell stimulation is required (Sieczkarski et al. 2002).  
We hypothesize that it should be possible to couple the geno- and phenotype of the 
AAV library mutants by induction of an unspecific uptake in the sense of 
macropinocytosis. To test this hypothesis the following experiment was performed. Virions 
were bound via antibodies to wells and cells were seeded on top to allow an uptake of all 
mutants that would be bound to the wells.  
To ensure binding of AAV particles, wells were coated with A20 antibody, which 
recognizes intact AAV capsids (Grimm et al. 1999, Wistuba et al. 1997) independently 
from their possible insertion in position 587. For proof of principle the wells were 
incubated with rAAV encoding GFP (rAAV/GFP) with 1x103 and 1x104 genomic particles 
per cell (GPC). Unbound rAAV/GFP was removed by a washing step with PBS/1% 
Tween20 and HeLa cells were seeded into the wells and incubated for 48h. GFP 
expression was then determined by FACS analysis. The same experiment was performed 
with A3/GFP, a recombinant AAV, where amino acids R-585 and R-588, which are mainly 
responsible for HSPG binding and in addition N-587, were substituted to alanine. This 
mutant is unable to bind to heparin and was described as HSPG knock out mutant (Wu et 
al., 2000). As a control, infections on HeLa cells were carried out with the same amounts 
of genomic particles as used for the uptake experiment. Experiments were also performed 
with an incubation time of 72 hours to analyze if the amount of GFP expressing cells can 
be improved by prolonging the incubation period. It was assumed that for A3 GFP 
expression was clearly increased by uptake in contrast to infection, whereas for rAAV/GFP 
similar results as for the infection were expected. 
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Regarding rAAV/GFP the uptake with A20 showed a transduction efficiency 
almost as high as with infection (Figure 3A). Slightly lower expression levels may be due 
to the loss of virions by the stringent washing step before applying the HeLa cells. For 
A3/GFP the transduction efficiency by infection was as low as expected for a HSPG knock 
out mutant and could be enhanced almost five-fold by uptake using 1x104 GPC (Figure 
3B). Prolonging the incubation time to 72 hours had only little effect on GFP expression in 
both cases (data not shown). Interestingly, increasing the amount of virus could not 
increase the GFP expression of A3/GFP to rAAV/GFP levels.  
Next, we wanted to analyze if the uptake was an unspecific mechanism or if AAV's 
primary receptor HSPG played the main part. For this infection and uptake were performed 
in presence of heparin which is able to block about 90% of infection of wtAAV on HeLa 
cells. If uptake was unspecific, heparin should not be able to block transduction and 
therefore GFP expression in these cells. 
For infection HeLa cells were seeded into wells and then infected with rAAV/GFP 
with 1x103 GPC, which had been incubated before with heparin solution (425 U/ml). Cells 
were then incubated for two days and the GFP expression level was determined by FACS 
analysis. For uptake A20 antibody was coated into wells and rAAV/GFP with 1x103 GPC 
was bound on top. The bound virions were then incubated with heparin and HeLa cells 
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Figure 3: Uptake of rAAV/GFP and A3/GFP versus infection
For uptake wells were coated with A20 antibody and incubated with rAAV/GFP (Figure A) or A3/GFP 
(Figure B) at GPC of 1x103 and 1x104. Wells were washed and then HeLa cells were seeded into the wells. 
Cells were analyzed by FACS analysis after 48h. For infection HeLa cells were seeded into wells and 
infected with rAAV/GFP or A3/GFP with GPC of 1x103 and 1x104. Cells were analyzed by FACS analysis 
after 48h. 
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were seeded on top and incubated for another two days. Again the GFP expression level 
was determined by FACS analysis. The transduction efficiency of uptake and infection 
without heparin was set to 100% and the fold reduction as percentage is shown in the 
diagram. 
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alyzed by FACS analysis after 48h. For infection HeLa cells were seeded into wells 
AV/GFP with 1x103 GPC after preincubation with heparin. Cells were analyzed by 
r 48h. 
ted the GFP expression for the infection was reduced to 6-8% when 
d and infection without heparin was set to 100%. For uptake the reduction 
cted as expected, heparin could still reduce the GFP expression to 30% 
% without heparin. Part of the uptake seemed to be blocked by heparin 
as not susceptible to the treatment with heparin.  
e if a coupling of the AAV library was possible by uptake, an uptake 
ing 15cm2 plates was performed. Briefly, a cell culture plate was coated 
y, blocked with Milk Powder (MP), and then incubated with the AAV 
mic particles per cell of 10, 100 and 1000. Unbound virus was washed 
ells were seeded onto the bound virions. Adenovirus was added for helper 
 replication and packaging. Cells were incubated for two days and then 
ell pellet was resuspended in lysis buffer and treated with repeated 
s. Viral DNA from virions contained in the lysate was purified, amplified 
ed into the AAV pRC vector. Plasmids were transformed into bacteria, 
e picked and at least one hundred clones for each setting were sequenced. 
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For comparison the region of interest of the DNA library and the original 
uncoupled viral library obtained after packaging in 293 cells and purification by Iodixanol 
density gradient were cloned into AAV pRC vector, transformed into bacteria, and 
sequenced, again at least 100 single clones, and analyzed.  
 
The coupling state is reflected by the amount of stop codons detected, since stop 
codons would also be packaged if more than one capsid encoding plasmid was transfected 
into one cell, 12 stop codons in a hundred regarding the codon usage were statistically 
possible, and 8.6 out of a hundred occurred in the original library. 
 
 
 
 
 
viral pool 
uncoupled Uptake GPC 10 Uptake GPC 100 Uptake GPC 1000 
Stopcod.per 100: 8.6 Stopcod.per 100: 1.4 Stopcod.per 100: 2 Stopcod.per 100: 4.6 
Table 1: Frequency of stop codons after coupling by uptake (GPC 10, 100 and 1000) 
At least 100 sequences were analyzed and the number of stop codons was calculated per 100 sequences. 
 
Utilizing the number of stop codons as an indicator for the coupling state of the 
library, the number of stop codons should be markedly decreased. In addition, biodiversity 
of the library should be maintained. An indicator for this was the absence of duplicate 
sequences. 
Regarding single sequences about 40% of sequences in GPC 10 occurred more than 
once, which is to be regarded as a reduced biodiversity. Presumably, under these 
conditions not all of the 106 different genomes were able to transduce cells, resulting in the 
enrichment of given sequences. In the uptake experiments utilizing GPC 100 and 1000 
there were no duplicate sequences pointing to a better ratio between genomic particles and 
cells and a better diversity. The number of stop codons was lower as in the original library, 
which points to a well coupled library. The number of stop codons calculated per 100 
sequences increased as expected, when higher GPC were used, since in case of GPC 1000 
it was very likely that more than one viral mutant was able to be taken up by one cell. 
Taken together the uptake with GPC of 100 seemed to be appropriate in terms of the 
coupling of mutants and the maintenance of an adequate diversity of the AAV library. 
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Coupling of geno- and phenotype:   B) infection 
 
Coupling of AAV library by infection without loss of biodiversity will work, if 
each virion from the non-coupled AAV library contains at least one cell binding motif 
which renders the AAV particle infections. In addition to the uptake experiments the 
coupling was therefore also performed by infection. As for the uptake experiment different 
GPCs were tested to determine the optimal coupling efficiency retaining full biodiversity.  
HeLa cells were seeded into cell culture plates and infected with 10, 100 and 1000 
genomic particles per cell in the presence of adenovirus to allow replication and packaging 
of AAV. Cells were harvested and resuspended in lysis buffer. Viral DNA was purified, 
amplified by PCR and cloned into the AAV pRC vector. Plasmids were transformed into 
bacteria and single clones were picked and sequenced.  
 
viral pool 
uncoupled 
Infection  
GPC 10 
Infection  
GPC 100 
Infection  
GPC 1000 
Stopcod.per100:8.6 Stopcod.per100:1.2 Stopcod.per100:0 Stopcod.per100:0 
 
 
 
Table 2: Frequency of Stop codons in infection experiment with GPC 10, 100 and 1000 
At least 100 sequences were analyzed and the number of stop codons was calculated per 100 sequences.
As observed for the coupling by unspecific uptake a comparatively high number of 
sequences occurred more than once when a GPC of 10 is used. The diversity of the library 
was clearly higher with GPCs of 100 and 1000 with no duplicate sequences and the 
number of stop codons, as an indication for the coupling state, was down to zero with 
GPCs of 100 and 1000 (Table 3). Even with an amount of 1000 genomic particles per cell 
a coupling of geno- and phenotype was accomplished. Since the coupling rate and 
biodiversity of the library seemed to be better when coupling was performed by infection 
(according to the frequency of stop codons per 100 sequences) the library coupled by 
infection was chosen for all following selection experiments. 
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Further analysis of geno/phenotype of coupled viral libraries 
 
In the previous experiments it was shown that the coupling of geno- and phenotype 
could be accomplished, no matter if coupling by infection or uptake was applied. 
To further prove that the library was indeed coupled after a first uptake or infection 
step, the coupled libraries were submitted to another round of infection and uptake, 
respectively. A clear difference of the 7mer sequences should be seen after submission of a 
coupled AAV library to an uptake or infection experiment, respectively. No mosaic capsids 
were expected in case of a coupled library. In general, AAV capsid variants, recovered 
after infection of cells with a coupled library, should harbour a genome with a higher 
content of positively charged amino acids. In contrast, the repetition of uptake with a 
coupled library should not show any significant differences to the sequences obtained from 
the former round, which in addition would prove the unspecificity of the uptake process.  
To investigate this, both libraries coupled by uptake or infection were submitted to 
a new round of uptake or infection and progeny virus was sequenced as described above. 
The sequences were analyzed for the overall net charge. Results are exemplarily shown for 
round II Uptake GPC100 and round II infection GPC 1000 (Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Uptake II net charge Infection II net charge 
VNDRLPS neutral SALNLQG neutral 
GIDLARS neutral VPPRDER neutral 
NVLGSGQ neutral TSATTPR + 
ASTQPQL neutral DRSPVVR + 
REQRETA neutral STPPSGR + 
IQGSPQG neutral PLASNPR + 
NESARSL neutral ISPKPQR + 
AEDRVTT - NTTLSCR + 
AQRSPQG + SRTVLTR + 
RAPNGGS + NSSGRDR + 
KVVGSGR + SGSQSIR + 
TQSPVQR + ATPATPK + 
GKARTSE + GTRGNLG + 
LARNQSG + RGATTGP + 
VKLGAAS + GRSGVQI + 
SVRAGSS + KLDQMRP + 
ASGSSPR + ATGRAPT + 
ANQRGPT + STKPGVA + 
RIERLAY + SLSQRAP + 
DKTGSKP + APSPRSI + 
Table 3: Representative example of 20 insertion sequences detected in round II of uptake GPC 100 and 
infection GPC 1000 
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Again the frequency of small amino acids like serine or glycine was increased and 
the number of bulky ones like phenylalanine or tryptophan was decreased similarly to the 
results obtained for coupling by uptake or infection. Striking was the increased frequency 
of arginine at position 7 after the second round of infection. Whereas only 3 out of 20 
sequences from the uptake experiment contain an arginine or lysine at position 7 (15% 
compared to 13% expected when completely random), 55% of the sequences after 
infection contain positively charged amino acids at position 7. Overall, 80% of all 
sequences after infection have a net positive charge, 20% are neutral, compared to 61% 
positively charged, 4% negatively charged and 35% neutral sequences found after uptake. 
These results, therefore, support that i) the libraries are indeed geno/phenotypically 
coupled and ii) uptake is rather unspecific. 
 
 
Selection of AAV particles with specific affinity for a target 
antibody from the coupled viral library 
 
The AAV library has been initially designed to select retargeting mutants which are 
able to specifically and efficiently infect a desired cell line. Selections have been 
successfully performed in the past as Luca Perabo was able to select three receptor-
targeting mutants on different target cells. These mutants transduced target cells with an up 
to 100-fold increased efficiency, in a receptor-specific manner and without interacting with 
the primary receptor for wt AAV (Perabo et al. 2003). Here, AAV mutants were to be 
selected which are able to specifically bind to the idiotype of the antibodies they are 
selected on (Figure 5). Selected AAV mutants should, therefore, carry epi- or mimitopes of 
the antibody's target (the respective antigen of the antibody used). 
In the first step the target antibody was coated to an appropriate cell culture plate at 
a concentration of 50-750µg per 15cm2 plate. The uncoated surface was then blocked with 
Milk Powder, followed by incubation of the coupled AAV library (see Coupling of geno- 
and phenotype by infection) on the coated antibodies.  
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Figure 5: Selection procedure for selection of AAV library mutants specific for antibodies 
Antibodies were coated to cell culture plates and after blocking incubated with the AAV library coupled by 
infection. Cell plate was washed to remove unbound mutants and HeLa cells were seeded into the plate. 
After 48h cells were harvested, lysed and the viral progeny was analyzed and submitted to another round for 
further selection. 
After adequate washing HeLa cells were seeded into the plate to allow AAV uptake 
and coinfected with adenovirus for replication and packaging. Cells were harvested and the 
lysates containing the virus were used further on as described above. The genomic titers 
obtained after each round were then quantified and sequences of single mutants were 
determined by sequencing.  
 
Selection of AAV capsid variants against target antibodies Omalizumab 
(Xolair®) and IgG-KLH 
 
During this thesis the following antibodies were used for the selection of anti-
idiotype AAV vectors. In first experiments the anti-human IgE antibody Omalizumab 
(Xolair®) was chosen, because this antibody has already been approved in therapy against 
allergic disorders in moderate to severe allergic asthma and specific mutants derived from 
this selection should be interesting candidates for drug development. The epi/mimitope of 
IgE bound by Omalizumab is not published and it is not known if it is a linear epitope or if 
a secondary structure of IgE is necessary for binding of Omalizumab. Furthermore, we 
used an anti-mouse IgG antibody directed against KLH (Keyhole Limpet Hemocyanin) in 
order to use an antibody which is known to recognize a linear epitope. 
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Selection on Omalizumab (Xolair®)  
With regard to developing an AAV based vaccine to treat allergic disorders we 
used the monoclonal antibody Omalizumab (Xolair®). Omalizumab is a humanized 
monoclonal antibody that selectively binds to human immunoglobulin E (IgE). 
Omalizumab binds IgE at the same site as the high-affinity receptor FcεRI, thereby 
reducing the amount of free IgE that is available to bind to the receptor. Levels of free IgE 
in the serum are reduced and, as consequence, the number of FcεRI receptors on basophils 
and other effector cells declines.  
Before starting with selections, the binding affinity of Omalizumab to the cell 
culture plate was determined by ELISA. For this, the antibody was coated in serial dilution 
into 96-well plates from Nunc, the same material that was used for the selections later on.  
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ure 6: Detection of Omalizumab with anti-human IgG1k and anti mouse IgGγ
alizumab was coated to Nunc well plates in dilutions from 500ng/well to 20ng/well and incubated with 
tin-conjugated anti-human IgG1k and anti-mouse IgGy antibody. Bound antibody was detected and 
ntified by Streptavidin-POD and subsequent enzyme reaction. 
After incubation unbound antibodies were washed away and the wells were 
bated with blocking solution (Milk Powder). Coated antibody was incubated with 
nylated anti-human IgG for detection of Omalizumab or anti-mouse IgG as control. 
eafter an enzyme reaction with Streptavidin-POD was performed and quantified, 
ing that Omalizumab bound well to the cell plate.  
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Omalizumab was able to coat to the cell culture plates and could be nicely detected 
by anti-human IgG, but not by anti-mouse IgG as expected. 
Next, four selection rounds were performed on Omalizumab with the coupled AAV 
library generated by infection, monitoring the genomic titers and the selected sequences 
after each round. In analogy selection rounds on PBS coated plates were carried out as 
negative control.  
The cell lysates, after repeated thaw/freeze cycles of the cell pellet, from each 
round were used for further analyses. Viral DNA was extracted from AAV capsids in the 
cell lysates and the genomic titers were determined.  
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e 7: Genomic titers of selected mutants on Omalizumab round I to IV
gure shows the genomic titers determined after round I to IV of selection for selections carried out 
alizumab and on PBS coated wells, respectively, with the library coupled by infection. 
If one or few variants of the AAV library display a sequence within 587 able to 
te binding to Omalizumab, first a drop in titer is expected, because in the first round 
ount of the respective mutants is very low. Then round after round this mutant 
 be amplified and should show an increase in titer. However, for AAV selection on 
zumab such an increase in genomic titers could not be detected. Titers yielded did 
en exceed the titers that were obtained by selection on PBS.  
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Characterization and specificity of selected mutants 
After each selection round fifty to a hundred clones were analyzed and their 
sequence was determined. For this the extracted viral DNA from each round was amplified 
by PCR and cloned into the AAV pRC vector. The plasmids were transformed into 
bacteria and single colonies were picked and analyzed by sequencing.  
With each selection round the diversity of sequences clearly decreased and some 
sequences became more prominent within the different rounds. After each selection round, 
other sequences were enriched. Only one single sequence stood up to others in course of 
the four selection rounds, VYSPTGK, which was identified as a predominant sequence 
after selection rounds 3 and 4. Another sequence, SDAPLPR, disappeared after the second 
selection round while being predominant after rounds 1 and 2. Importantly, none of the 
sequences identified from the Omalizumab selections corresponded to the sequences 
identified in the control PBS selection.  
 
Omalizumab 
selection I. round II. round III. round IV. round 
SDAPLPR 69.0% 83.1% 0% 0% 
VYSPTGK 16.7% 7.9% 58.4% 100% 
TSASRAP 0% 0% 8.3% 0% 
others 14.3% 9.0% 33.3% 0% 
 
 
The three most prominent sequences identified were cloned into an AAV-helper 
plasmid and the respective plasmids were used to package recombinant AAV vectors 
encoding a self complementary GFP (scGFP) transgene. Self complementary transgene 
vectors are, in contrast to single stranded AAV transgene vectors, able to bypass second-
strand synthesis, which is the rate-limiting step for AAV in host cell DNA synthesis 
(McCarty et al., 2001). The respective AAV mutants yielded comparable titers to wtAAV 
and were tested for specific binding to the Omalizumab antibody by Dot Blot. For this IgE 
antibody as positive control, the intact viral capsids of the selected variants, and wtAAV as 
negative control were blotted to a nitrocellulose Hybond membrane (Amersham) and then 
detected by Omalizumab, which was also used for the selection. Bound Omalizumab was 
detected by anti-human IgGγ HRP and quantified by subsequent enzyme reaction. The blot 
was then stripped and detection was repeated with the capsid specific antibody A20, as the 
A20 epitope is not marked by the inserted sequence at position 587, recognizing AAV 
Table 4: Frequency of occurring sequences   
At least one hundred clones were sequenced and analyzed and the amount of each selected 
sequence was set in relation to the others. 
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capsids. All AAV variants should be detectable by A20, whereas only the selected mutants 
should bind to Omalizumab if the selection was indeed specific for the idiotype of the 
selection antibody used.  
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Figure 8: Omalizumab specific Dot Blot
Selected mutants were blotted to nitrocellulose membrane and detected by Omalizumab (A). The blot was 
 by A20 antibody (B). The mutants were blotted in two 
AP in 
stripped and bound mutants were detected
concentrations, 5x1010 capsid particles and 1x1010 capsid particles. A2 to A9 shows the IgE positive 
control and H2 to H9 wtAAV as control. Mutant SDAPLPR is blotted in C9 and C10; mutant TSASR
D4 and D5 and mutant VYSPTGK in D7 (Other Dots show mutants not described in this work). 
A
according to the Dot Blot data, there is a clear difference in the affinity for the three 
sequences analyzed. In this case the variant SDAPLPR was recognized better by 
Omalizumab as variant TSASRAP and VYSPTGK, indicating that there is a difference in 
the affinity of the variants to Omalizumab. 
 
 
 
To proof the concept of selection of anti-idiotype AAV vaccine,
ed with an antibody, which was known to recognize a linear epitope. The mouse 
anti-KLH IgG was obtained from a mouse immunized with purified KLH (Keyhole Limpet 
Hemocyanin) and is an IgG1 isotype antibody. 
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Again the binding affinity of the antibody to the plate was tested by ELISA. Mouse 
anti-KL
 
 
on
m
H IgG, A20 antibody and PBS as negative control were coated to a Nunc 96-well 
plate and incubated over night at 4°C. Wells were washed the next day and blocked with 
BSA. Bound antibodies were detected with biotinylated anti-mouse IgG and quantified by 
enzyme reaction with Streptavidin-POD. 
 
0
0.5
1
1.5
2
2.5
500 250 125 62.5 31.25 15.6 7.8 3.9
ng/well
O
D
 E
LI
SA
 4
50
nm
A20 anti-KLH IgG PBS
 
 
 
 
 
 
 
 
se
DN
de
ro
 Figure 9: Detection of mouse anti-KLH IgG with anti-mouse IgG
n dilutions from 500ng/well to 
und 
Mouse anti-KLH IgG, A20 and PBS were coated to Nunc well plates i
4ng/well for mouse anti-KLH IgG and incubated with biotin-conjugated anti-mouse IgG antibody. Bo
antibodies were detected and quantified by Streptavidin-POD and subsequent enzyme reaction. Th
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und no ree selection rounds were performed with the AAV library coupled by infection 
 of the selection the genomic titers for the selection on 
 anti-KLH IgG (see Coupling of geno- and phenotype by infection). Again 
rounds on PBS coated plates were performed as a negative control. The viral 
s extracted from the mutants in the cell lysates and the genomic titers were 
d as described above. 
ithin the three rounds
ti-KLH IgG clearly increased this time compared to the PBS control. In the third 
genomic particles were detectable for the PBS control anymore. 
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Figure 10: Genomic titers of mutants selected on IgG-KLH
Genomic titers were determined by Light Cycler PCR after each round and the total number of genomic 
particles after each round was calculated. 
Characterization and specificity of selected mutants 
Extracted viral DNA from the lysates after the first and the second round was 
amplified, cloned into the AAV pRC vector and the resulting plasmids were transformed 
into bacteria. Fifty to a hundred single clones were analyzed to determine the sequences 
inserted in 587 of the respective clones. For mouse anti-KLH IgG 5 sequences could be 
determined which were clearly prominent. All sequences, comparing mouse anti-KLH IgG 
and PBS control selection, were different, arguing for target specificity of the selected 
clones. 
 
 
 
 
 
 
IgG I. Round II. Round 
ARAGLPG 22% 0%  ▼ 
LRPDARP 15.4% 50% ▲ 
PRTDSPR 26.4% 45% ▲ 
PTLTPPR 19.8% 0%  ▼ 
STLAPPA 2.2% 0%  ▼ 
Others 14.2% 5%   ▼ 
Table 5: Frequency of identified sequences   
At least one hundred clones were sequenced and analyzed. The amount of each specific sequence was 
 set in relation to the total sequences analyzed. 
 
The selected sequences were cloned into AAV helper plasmid, which were used to 
package recombinant AAV vectors encoding for scGFP as transgene as described before 
for the mutants selected against Omalizumab. The titers obtained for the mutants were 
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comparable to titers determined for wtAAV. These mutants were then tested in anti-KLH 
specific Dot Blots. For this KLH peptide as positive control, the intact viral capsids of the 
selected mutants, and wtAAV as negative control were blotted to a nitrocellulose Hybond 
membrane (Amersham) and then detected by mouse anti-KLH IgG, which was also used 
for the selection. Bound anti-KLH IgG was detected by anti-mouse IgGγ HRP and 
quantified by enzyme reaction. The blot was then stripped and detection was repeated with 
the capsid specific antibody A20. All AAV variants should be detectable by A20, whereas 
only the selected mutants should bind to the anti-KLH IgG if the selection was indeed 
specific for the idiotype of the selection antibody used.  
A) anti-KLH IgG B) A20 antibody 
 
 
 
 
 
Figure 11: anti-KLH specific Dot Blot 
Selected mutants were blotted to nitrocellulose membrane and detected by mouse IgG-KLH (A). The blot was 
stripped and bound mutants were detected by A20 antibody (B). A1 to A8 shows the KLH positive control and 
H1 to H8 wtAAV as positive control for A20 antibody. The mutants were blotted in two concentrations, 1x1010 
capsid particles and 5x1010 capsid particles. Mutant ARAGLPG was dotted in C1, C2; LRPDARP in C4, C5; 
PTLTPPR in C7, C8; PRTDSPR in D1, D2 and STLAPPA in D4, D5.  
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All five mutants were detectable by A20 antibody, indicating that the intact capsids 
could be blotted to the membrane. Four mutants also showed a signal with the KLH 
specific antibody anti–KLH IgG, suggesting that four out of five mutants showed specific 
binding to the antibody they were selected on, whereas ARAGLPG and LRPDARP 
showed a higher affinity to anti-KLH IgG in the Dot Blot than the other mutants. 
Vaccination experiments in rabbits will be performed by Medigene AG with the two 
mutants in this blot, which showed the best signal with anti-KLH IgG, ARAGLPG and 
LRPDARP.  
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3.3. Discussion and Outlook Chapter II 
 
Allergic disorders are one of the increasing diseases of the industrial countries. The 
prevalence of asthma in Western Europe has doubled in the last decade, leading to an 
estimated prevalence in the adult population of 10 to 15% (Jonkers et al. 2005). While 
milder forms like hay fever can be easily treated with today's medicine, such as 
antihistamines and corticosteroids for moderate forms of asthma, more severe forms like 
the walnut or bee sting allergy represent life-threatening illnesses for the patient and are 
greatly interfering with the patient's life quality.  
In general the immune system shows tolerance against self antigens, like IgE as in 
the case for allergies, tumour-associated antigen (TAA) or beta-amyloid, because these 
antigens are not recognized as immunogenic. For active immunization against these 
antigens, their antigenic structures, or part of it, can be presented by anti-idiotypic 
antibodies in another molecular context to induce an immune response against the original 
self antigen. It was shown that anti-idiotypics can break immune tolerance, but the titers 
reached were usually fairly low.  
An AAV mutant, representing an anti-idiotypic sequence, could combine the 
advantages of an anti-idiotypic vaccine and an efficient immune response, evoked by the 
viral polymeric structure. 
The AAV library represents a suitable tool to select mutants, which display the 
desired anti-idiotypic sequence, e.g. by selection on anti-IgE antibodies. Selections here 
were performed using a diversity of 4x106 AAV variants in a solid phase selection 
procedure.  
Since the number of patients with allergic disorders and also the number of severe 
forms of allergic diseases are dramatically increasing in the industrial countries, a new 
efficient treatment will be of great value for the patients suffering from these diseases. 
 
Uptake seems to allow unspecific internalization of AAV 
AAV infects cells by interaction with its primary receptor HSPG, which is found on 
a wide variety of cells and therefore establishing AAV's broad tissue tropism (Summerford 
and Samulski, 1998; Kern et al., 2003). For the performed selection procedure, it had to be 
guaranteed that the bound mutants were taken up by the host cell for replication, no matter 
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what tropism the mutant would show. Macropinocytosis is an unspecific mechanism, with 
which cells are able to take up viruses or other antigens without receptor interaction 
(Sieczkarski et al. 2002). This mechanism is mostly used by antigen presenting cells, 
which are responsible for recognizing material which has to be eliminated.  
For the selection procedure a similar approach was to be achieved by simply 
seeding HeLa cells on top of antibody bound mutants. To test if viruses were in fact taken 
up by HeLa cells independent of HSPG receptor binding and able to replicate within the 
cell, different uptake experiments were performed (compare Coupling of geno- and 
phenotype by uptake). 
To establish the system, rAAV/GFP, which corresponds to a wildtype capsid 
carrying a GFP transgene expression cassette, was bound to the immobilized A20 
antibodies in a first approach. HeLa cells were then seeded on top of the A20-rAAV/GFP 
complexes, and the transduction efficiency by means of GFP expression was measured 48h 
later. As positive control, infection of HeLa cells with rAAV/GFP was performed (Figure 
3). The results clearly show that the transduction efficiency achieved by uptake was almost 
as high as with infection. Fairly lower transduction efficiencies in case of uptake might be 
due to the washing step applied before seeding the HeLa cells. Some virions might get lost, 
which then cannot contribute to the overall transduction efficiency. To show that uptake is 
unspecific and thus independent of the capsid sequence (and, therefore, independent of 
receptor binding), the same experiment was carried out with an A3/GFP mutant, whose 
heparin binding residues at positions R-585 and R-588, and in addition N-587, were 
mutated to alanine residues. This mutant is unable to bind to heparin and was described as 
HSPG knock out mutant (Wu et al., 2000). In fact, in infection experiments A3/GFP was 
only able to transduce HeLa cells with up to 3% transduction efficiency (GPC of 1000), 
whereas in uptake experiments, the transduction efficiency was increased to about 15%. 
This means a five fold increase in transduction efficiency. The fact that GFP expression 
mediated by uptake of A3/GFP cannot be increased to rAAV/GFP levels, neither by higher 
virus concentrations nor by prolonging the incubation time of the cells to 72h, might result 
from inefficient intracellular processing or a different trafficking pathway, that A3/GFP 
uses once it is internalized by the cells. Wu et al. (2000) first described this mutant as 
heparin independent and showed that it can only poorly bind to heparin column, but did not 
test further if A3 is taken up by the cell and able to travel to the nucleus or not. 
Interestingly, a heparin Nonbinder pool selected from a coupled AAV library which only 
poorly infected HeLa cells as expected (see Chapter III Figure 2 Infection and Uptake 
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experiments with the Binder and Nonbinder fractions) is able to transduce HeLa cells rather 
efficient if the uptake technology is applied. This strongly supports the theory that uptake 
is suitable for efficient, sequence-unspecific cell transduction, and that the specific mutant 
A3/GFP has unique features which interfere with subsequent intracellular trafficking. 
The experiment was repeated with rAAV/GFP, this time using heparin to prevent 
internalization mediated by the primary receptor of AAV, the heparan sulfate proteoglycan 
(HSPG). Both infection and uptake were performed in the presence of heparin. Infection 
could be blocked, up to 92-94% by heparin, whereas uptake was still blocked up to two 
thirds. The partial blocking of the uptake by heparin could be explained by different uptake 
routes that the virions might use. Since the cells are seeded on top of the virions, bound to 
antibodies in the cell plate, macropinocytosis might be an option for the virions to enter the 
cell. In other events the secondary receptors of AAV may facilitate the uptake. Other 
virions might still use their primary receptor HSPG, which can then be blocked by heparin. 
On the other hand heparin itself might prevent other events than just the interaction of 
AAV with HSPG. 
 
Homogeneous library mutants result from coupling through uptake or 
infection 
The original viral library consists of inhomogeneous mutants with mosaic capsids 
arising from the fact that many library plasmids are transfected into each cell during the 
production step of an AAV library in 293 cells. For the application of selection on 
antibodies, it is absolutely necessary to use mutants which genome encodes the same 
insertion as the capsid displays. To couple geno- and phenotype of the library for the 
selection protocol, the virions were submitted to uptake and infection experiments, varying 
the amounts of genomic particles per cell. To test for coupling efficiency and biodiversity 
of the new libraries generated, sequences of the resulting libraries were analyzed in terms 
of frequency of stop codons and diversity and compared to the original library (see 
Coupling of geno- and phenotype by A)uptake/B)infection).  
Depending on the GPC used, differences were found when looking at stop codons 
and repetitive 7-mer sequences. Using 10 genomic particles per cell for uptake and 
infection, a few sequences were found more than once in a hundred sequences analyzed. 
The biodiversity was clearly higher when using a GPC ratio of 100 or 1000. Under such 
conditions no single sequence was found more than once in a hundred sequences analyzed. 
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The decreased diversity in GPC 10 might be explained by the low multiplicity of infection 
(MOI) used. The infectious titer of wtAAV is usually lower than the determined genomic 
particle titer. Transferring this onto the AAV library, not all of the 10 genomic particles per 
cell will result in genome transcription, explaining why the diversity decreases when GPC 
10 is used, in uptake as well as in infection experiments.  
The number of stop codons was analyzed to draw conclusions concerning the 
coupling state of the obtained libraries. The original pool still contained 8 stop codons per 
100 sequences, whereas the number of stop codons was clearly reduced in all cases where 
GPC ratios of 10, 100 or 1000 were used for uptake as well as for infection experiments. In 
case of uptake experiments 1 to at maximum 4 stop codons (GPC 1000) were found. In 
case of infection experiments none to just 1 stop codon was found in a hundred sequences 
analyzed. Obviously, libraries resulting from infection experiments are coupled to a higher 
degree compared to libraries resulting from uptake experiments. 
A reason for this major difference in the coupling state may be due to the coupling 
procedure used for uptake experiments. Virions are bound to A20 antibodies being coated 
to the tissue culture dishes. If for some reason the A20-virion complexes are not evenly 
distributed in the plate, rather a "virion pool" than single virions might be taken up by 
some cells, whereas other cells do not take up any virus. Such events could lead to the 
successful packaging of AAV genomes harbouring a stop codon in the inserted 7-mer 
sequence, despite the fact that these genomes code for non-functional cap proteins. In 
infection experiments, an even distribution of the virions might be more easily achieved, 
ensuring that at most one particle is taken up by a single cell. 
Importantly, the biodiversity deduced from the number of repetitive sequences was 
high when using at least 100 genomic particles per cell, both for uptake and infection 
experiments. As 4 stop codons were found on case of uptake and GPC of 1000, a GPC of 
100 should be chosen to couple an AAV viral library without losing biodiversity. In case of 
coupling by an infection step, a GPC of 1000 should be chosen, as 1 or less stop codons 
were found for both conditions, GPC 100 and 1000, and as no repetitive sequences were 
found under both conditions. A higher GPC in this case guarantees a higher degree of 
biodiversity, although no difference could be found when analyzing only 100 sequences. 
To have more confidence, ideally 300 to 1000 sequences should be analyzed. 
 
Müller et al. (2001) generated a random AAV peptide library, also containing 
insertion of 7-mer peptides in position 587, in a three-step system to obtain virions 
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encoding of the displayed peptides by the packaged genome. In contrast to this approach, 
they packaged the library containing mutant cap genes into capsids, made up partially of 
wild-type VP proteins, by cotransfecting wildtype rep-cap plasmids lacking the inverted 
terminal repeats (ITRs) required for encapsidation. By this they obtained "AAV library 
transfer shuttles", which partly resembled wildtype capsid and bound heparin at a level of 
approximately 60% of wtAAV (Muller et al. 2001). To obtain coupled AAV library 
mutants, they transduced 293T cells with the AAV transfer shuttles with MOI of 1 to 5. 
They demonstrated by sequencing of a representative number of randomly selected clones 
that the resulting AAV library showed a diversity comparable to the plasmid library from 
which it was generated. A major problem in this approach is the fact that the library 
production allowed packaging of wtAAV genomes to some degree, probably resulting 
from homologous recombination taking place during packaging and thereby limiting the 
application for selection on cell types susceptible to AAV infection. For the selection on 
antibodies, this might also be disadvantageous, since mutants which can infect the 
producer cell line, in this case HeLa cells, more efficiently, but show low affinity to the 
antibody they are selected on, might outweigh high affinity mutants with poor ability to 
transduce the producer cells.  
Interestingly, the coupling by infection experiments with GPC 1000 in this case 
seemed to result in a good coupling state (low number of stop codons) and without loss of 
biodiversity, compared to the coupling with AAV transfer shuttles, done by Müller et al.. 
The coupling of geno- and phenotype of the AAV library will work if each virion of the 
non-coupled library contains at least one heparin-binding motif which renders the AAV 
particle infections. A heparin-binding motif is reconstituted if the last amino acid of the 
random 7-mer sequence contains a positively charged amino acid R or K or an overall net 
positive charge is achieved by the insertion (compare Chapter III, Heparin Binder and 
Nonbinder, Table 1). Looking at the arginine positions R585 and R588, the insertion of a 
peptide between R585 and R588 (Figure 12A, B) could cause their spatial separation or 
sterically block the heparin binding ability. In either case, bulky amino acids are prone to 
lead to one or both of these events (Figure 12C, D). If the peptide consists of small 
residues, the insertion could be less invasive and the structure of the HSPG binding motif 
maintains functional (Figure 12E). Insertion of positively charged peptides could lead to a 
HSPG binding phenotype in combination with one of the original arginines (Figure 12F) or 
independently from them (Figure 12G). The proximity of R588 to the last position of the 
inserted peptide could facilitate reconstitution of a functional motif if an arginine is present 
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at this latter position (Figure 12H). It should be noted that this behaviour could be due to 
the particular sequence of the construct that was used, where the 7th position of the 
randomized peptide and R588 are separated by two residues resembling the wild-type 
situation. Thus, multiple ways for the generation of a heparin/HSPG binding phenotype 
exist. 
Therefore, most of the non-coupled virions indeed are able to bind to the cell and to 
be replicated in the cell without the need of an AAV transfer shuttle. 
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major changes in the characteristics of the library happened and proofing that uptake 
happens in an unspecific manner. In case of infection on the other hand a clear shift to 
positive amino acids, especially arginine, strikingly at position 7, was observable. The 
coupled library consists of a homogeneous capsid carrying exactly the same genome 
encoding these capsid proteins. All particles which are no more able to bind the cell via the 
inserted sequence or the original R585/R588 if the inserted ligand is not destroying the 
natural heparin/HSPG binding motif (Figure 12C, D) will be lost. The increased prevalence 
of arginine or other positively charged amino acids, like the prevalence of small amino 
acids such as serine or alanine, hint indeed to a conservation of the capsid's ability to bind 
to heparin by the R585/R588 or a corresponding restored motif (Figure 12). 
 
Selection of anti-idiotypic AAV mutants on antibodies by solid phase  
After establishing the conditions for the selection procedure, the AAV library was 
submitted to selection on the anti-IgE antibody Omalizumab to identify mutants which 
could then be used for a vaccination approach. Omalizumab was chosen as target antibody 
as the therapeutic concept of the anti-IgE drug is clinically validated, and this monoclonal 
antibody is already approved as a passive vaccine in asthmatic patients, both in the USA 
and in Europe. Four rounds of selection were carried out, using the library coupled by 
infection. As a control the same selection protocol was applied to plates where instead of 
the antibody only PBS was coated instead of the antibody. For an ideal selection process 
one would expect that the genomic titer of the virion population obtained after each 
selection round will increase, since mutants with a sufficient binding affinity to the target 
antibody should be enriched. In case of the selection against Omalizumab, however, no 
such increase of genomic titers of the recovered AAV particles could be observed. The 
titers remained more or less constant after all selection rounds and the selection behaviour 
based on the genomic titer was similar to the PBS control. From these findings it was 
expected that no specific sequences recognized by Omalizumab were enriched during the 
selection procedure. Therefore, about 100 sequences cloned after each single selection 
round were analyzed by sequencing of the 587 region. A total of 3 individual sequences 
was identified which were highly repetitive with frequencies of 12 to 95% after a given 
selection round. However, only one sequence – VYSPTGK – was clearly enriched during 
the four rounds of selection. Two sequences occurred early in the selection process and 
then disappeared again, others appeared later during the selection process, and one 
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sequence even popped up after only the third selection round. All selected sequences were 
tested for IgE specific binding in Dot Blot experiments. Clear and IgE-specific signals with 
different intensity were obtained for selected AAV in the performed Dot Blot. 
Interestingly, the only sequence which was continuously enriched during the selection 
process was not recognized by Omalizumab. Perhaps AAV particles encoding this cap 
sequence have only a comparable low affinity to Omalizumab, but its genome is 
excellently taken up by and reamplified in the transduced cells. Also the fact that the 
selected mutants did not show increasing titers in the continuous selection rounds might be 
explained by a weaker affinity to Omalizumab combined with an efficient replication in 
HeLa cells. 
As a completely independent experiment and to confirm the usefulness of a coupled 
library for the selection of anti-idiotypic AAV particles, selection of AAV variants on a 
anti-KLH antibody (mouse IgG1), known to recognize a linear epitope of KLH, was 
performed. Interestingly, in this experiment increasing genomic titers after each of the 
three selection rounds performed were detectable, in agreement with our hypothesis, 
indicating that selection of one or a few specific sequences and their enrichment had 
indeed taken place. 50 to 100 clones obtained after the first and second selection round 
were sequenced. This analysis revealed that five sequences were prominent after the first 
selection round, but only two of them prevailed (95%) after the second selection round. 
Dot Blot experiments indicated that AAV particles with those 5 sequences have different 
affinity for the anti-KLH antibody. Two of them bind with a rather high efficacy, two of 
them have intermediate to low affinity and one has no detectable affinity at all. 
Interestingly, only one of the two sequences left after the second round of selection 
belongs to the high-affinity binders, whereas the other sequence has only little affinity for 
anti-KLH IgG. This seems to confirm the theory that there is the interplay of binding 
affinity for the target antibody on the one hand and amplification efficiency in the cell on 
the other hand. For this reason, it seems very important to investigate all repetitive 
sequences obtained after each selection step for their respective affinity in Dot Blot 
experiments.  
 
The selections of coupled AAV libraries performed on the antibodies Omalizumab 
and anti-KLH IgG showed that the selection of a specific mutant is possible. However, the 
experiments have also shown that repeated selections will not lead to the isolation of only 
one high affinity binding mutant. In contrast, several sequences with different affinities for 
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the respective antibodies are being identified. Although a preselection of suitable mutants 
can be performed based on in vitro assays such as Dot Blot, animal vaccination 
experiments are indispensable to finally identify the one AAV variant which is best suited 
to induce polyclonal antibodies against the target antigen with all desired and required 
properties also carried by the monoclonal selection antibody.  
The production of sufficient antibody titers for an active immunization approach 
highly depends on the immunogenicity of the viral structure. Several studies have 
determined a high prevalence of serum antibodies (Ab) against the AAV capsid in the 
human population. They could show that between 30 and 96% of human beings are 
seropositive for AAV specific Ab and that 18 to 67.5% of them are neutralizing antibodies, 
depending on age and ethnic group. (Blackow et al. 1968; Chirmule et al. 1999; Erles et al. 
1999; Moskalenko et al. 2000). These neutralizing Ab can cause considerable problems, 
especially when readministration of the vector is required in gene therapy applications. 
Acute inflammation due to activation of the innate immune system, and expression of 
chemokines and cytokines, which has been strongly observed for adenovirus, does take 
place very gentle after AAV transduction and is only very short lived (Zaiss et al. 2002). 
Therefore, AAV vectors seem to have markedly reduced inflammatory properties 
compared to other viral vectors such as adenovirus. For many viral vectors, a strong 
cellular immune response against the vector and the delivered transgene, which can cause 
severe complications for the treated patient, has been observed. This was probably the case 
for Jesse Gelsinger, who died in a Phase I gene therapy trial after application of an 
adenoviral vector (for further information see Teichler Zallen 2000). In contrast, after in 
vivo gene transfer of rAAV vectors, apparently no evidence for a cellular immune response 
to the transgene product, elicited by the presence of AAV, has been reported (Chirmule et 
al. 1999; Hernandez et al. 1999; Jooss et al. 1998; Chirmule et al. 2000). This may be due 
to the fact that rAAV fails to infect mature dendritic cells capable of stimulating antigen-
specific T-cell responses and therefore, the presentation of neoantigens might be inefficient 
(Jooss et al. 1998), but that rather high numbers of immature dendritic cells are 
transducable with AAV in vitro, a situation which in unlikely to occur in vivo. The study 
describes the in vitro transduction of immature dendritic cells by AAV which initiated 
subsequently a CD40-ligand dependent T-cell response against transduced cells (Zhang et 
al. 2000). The role of such immature dendritic cells for eliciting a cellular immune 
response after AAV transduction in vivo has to be further elucidated.  
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Manno et al. recently described an immune response against recombinant AAV 
capsids, in a phase 1 study in severe hemophilia B (2006). Preclinical studies in dogs 
revealed no immune response against the transgene or vector, but administration in humans 
showed a destruction of transduced hepatocytes by cell-mediated immunity targeting 
antigens of the AAV capsid. These events occurred 4 – 6 weeks after administration of the 
vector and in consequence led to decreasing titers of Factor IX expression.  
All these observations point towards a mainly humoral response against the AAV 
capsid, while a cellular immune response to the virion or to the delivered gene product is 
rare.  
The conflicting data presented by several studies indicate that the CTL as well as 
the humoral response to the delivered gene and the AAV capsid depends on a number of 
variables, including the nature of the transgene, the route and site of injection, the age, 
health and immunological background of the subject, the degree of contamination with 
helper virus proteins, and even the maturation state of antigen presenting cells exposed to 
rAAV administration. This implies the need for a better understanding of the immune 
response against AAV. Nevertheless, the studies indicate that AAV is able to elicit a 
humoral immune response and therefore can be used for active immunization approaches, 
where an polyclonal antibody response is to be provoked. The efficiency and the 
magnitude of antibody response have still to be elucidated, and importantly, the AAV 
vaccine has to have the potential to break tolerance against self-antigens such as IgE 
described in this thesis. If the particular structure and repetitiveness of the epitopes 
exposed on AAV should not be sufficient to break tolerance against the antigen, which is 
very unlikely, the immunogenicity of the viral capsid can be further improved by the 
addition of adjuvants such as Freund's Complete Adjuvants (FCA) in mouse or CpG in 
human, both stimulating TH1 immune responses. 
Other vaccination approaches for allergy include the design of IgE-based synthetic 
peptide immunogens (Wang et al. 2003). The known epitope for the binding of IgE to its 
high affinity receptor FcεRI was synthesized and immunopotentiated by linkage to a 
combinatorial T helper epitope derived from measles virus, UBITh®A, to provoke an 
immune response and allow active immunization. Wang et al. could show that a polyclonal 
antibody response could be generated in dogs and these antibodies blocked binding to the 
high affinity receptor FcεRI, and were sufficiently immunogenic to evoke functional anti-
dog IgE immune responses in dog. Besides the design and synthesis of immunogenic 
peptides, the target epitope has to be known in this approach. The coupled AAV library 
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allows the mapping of unknown epitopes and the selection of high affinity peptides in one 
step and in addition provides the polymeric structure to evoke a polyclonal immune 
response. 
 
Outlook 
Although we could demonstrate that the AAV library currently available is already 
suitable for the selection of AAV variants with the specific affinity for a target antibody of 
choice, there are several ways to improve the library on the one hand and the selection 
methodology on the other hand. For further improvements of the AAV library an extension 
of the insertion sequence from currently 7 to at least 12 up to about 34 amino acids should 
be feasible as a 34mer sequence directly cloned into this insertion site was well tolerated 
by AAV (Ried et al., 2001). This could increase the diversity of the library dramatically 
(whereupon a biodiversity of 1x108 to 1x109 will be the upper limit due to the restrictions 
such as cloning efficiencies and scale feasible) and allow the formation of secondary 
structures within the inserted sequence to expose more complex epitopes. The production 
of a library with an insertion sequence of 14 amino acids is on the way to widen the 
diversity of the library. Other insertion sites suitable to express foreign peptide sequences 
on the virus capsid have been identified and libraries cloned into these sites are currently in 
preparation. Another approach is the insertion of 14 random amino acids flanked by two 
cysteines residues on each side which would lead to formation of loop structure of the 
inserted random sequence due to disulfide bridging (Shi and Bartlett, 2003). With the 
insertion of an RGD-4C motif in position 520 and/or 584, AAV vectors could be generated 
which show eliminated heparin binding ability and a novel tropism to endothelial cells (Shi 
et al. 2006). The advantage of an extra loop mediated by flanking cysteine residues could 
be that such a structure would be protruding from the rest of the capsid and, therefore, 
could allow a better contact to the target antibodies in the selection process and a better 
presentation of the selected sequence later on in the vaccination step.  
 
The selection of AAV mutants on antibodies widens the application of the AAV 
library and allows selection of specific mutants for vaccination approaches. Extending the 
size of the insertion peptide of the library will provide a library with greater diversity for 
new selection approaches. 
 
Chapter III - Application of the coupled AAV library for selection of gene therapy vectors 66 
4. Chapter III - Application of the coupled AAV library for 
selection of gene therapy vectors 
4.1. Introduction 
The coupled AAV library, which was required for AAV anti-idiotype selection, is 
also a very useful tool for selection of gene therapy vectors. A major problem for 
application of AAV in gene therapy is the broad tropism of the vector in vivo. The primary 
receptor of AAV, HSPG (Summerford and Samulski 1998), a widely distributed negatively 
charged cell surface molecule, is thought to be responsible for this broad tropism. This 
hampers selective transduction of target tissue. Vectors aiming to redirect the tropism of 
AAV have been generated by insertion of ligands at position 587/588 of the AAV capsid 
(Büning et al. 2003a; Büning et al. 2003b). This is likely to interfere with the HSPG 
binding of at least two (R585 and R588) of the five positively charged amino acids of the 
recently identified HSPG binding motif (Kern et al. 2003; Opie et al. 2003), explaining the 
ablation of HSPG binding of some targeting vectors (Girod et al. 1999; Grifman et al. 
2001; Nicklin et al. 2001; Perabo et al. 2003; Ried et al. 2002). In some cases, however, 
binding was only partially affected (White et al. 2004), or even restored (Grifman et al. 
2001; Perabo et al. 2003; Work et al. 2004).  
 
AAV heparin Binder and Nonbinder pool 
With the coupled AAV library, the mutants can be differentiated into heparin 
Binder and Nonbinder and facilitate the selection of HSPG independent vectors. To 
investigate molecular mechanisms responsible for these differences in HSPG binding 
behaviour, the combinatorial library of AAV capsids carrying insertions of 7 randomized 
amino acids at position 587 (Perabo et al. 2003) and coupled by infection was applied to a 
heparin affinity column to separate heparin/HSPG binding from non-binding mutants.  
In the following the separation of Binders and Nonbinders is described and a 
selection on primary Hepatocytes as target cells was performed to show that by utilizing 
the Nonbinder pool a highly selective and efficient retargeting vector can be obtained. 
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4.2. Results 
Separation of Binders and Nonbinders by Heparin binding affinity 
In a first step the AAV library was coupled by infection of HeLa cells as described 
in Coupling of geno- and phenotype by infection. Briefly, HeLa cells were infected with a 
GPC of 1000 in presence of adenovirus and harvested after 48h. The cell pellet was 
submitted to repeated thaw/freeze cycles and the lysate was then purified by Iodixanol step 
gradient purification. To separate the mutants displaying sequences able to restore HSPG 
binding ability from mutants displaying peptides which ablate HSPG binding, the coupled 
library (about a total of 1x1011 genomic particles) was applied to a Heparin column 
(HiTrap, Amersham Bioscience).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Separation of Binder and Nonbinder pool   
The AAV library coupled by infection is separated by Heparin column. The flow-through was termed as 
Nonbinder pool and the Binder pool was eluted with 1M NaCl. 
The flow-through contained the Nonbinders, whereas the Binders were eluted from 
the column by 1M NaCl. Then both fractions were again purified by Iodixanol step 
gradient to concentrate the virions. Thereafter genomic titers of both pools were 
determined by Light Cycler PCR.  
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After the second purification step still genomic titers of 1x107 per µl (500µl total) 
were obtained. The Binder and the Nonbinder libraries were then characterized by 
sequencing. Therefore, viral DNA was amplified by PCR and cloned into the AAV pRC 
vector. The plasmids were transfected into bacteria and one hundred single clones were 
picked and sequenced. In addition, the viral DNA library and the AAV library after 
packaging were also sequenced and analyzed. 
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RVDPEAK  VGSDPSV -  acids. 
r (blue) or expected (black) frequency of each 
 population >80 clones were sequenced. *These 
ected but statistical assessment of the 
mber of clones.  
AAV and NB-AAV pool.  
e a weak charge considering the low pKa of 
 than expected statistical presence of 
ures of the oligonucleotides synthesis 
et statistical expectations.  
the amino acids proline (P), glycine (G) 
cine (L), phenylalanine (F), tryptophan 
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(W) and tyrosine (Y) (Table 1A). Since P, G, and A are three of the four smallest amino 
acids, whereas F, Y and W are three of the four biggest, this bias suggests that the 
packaging process selects against bulky inserts which would introduce dramatic structural 
rearrangements and have a deleterious effect on capsid structure. In addition, prolines 
could favour spatial accommodation of the peptide by introducing kinks and reducing its 
bulkiness. Cysteine on the other hand might lead to structural problems due to disulfide 
bridging with other cysteine residues of the AAV capsid. 
The Binder pool showed a significant increase of arginine residues (Figure 1B). 
Strikingly, arginines were particularly frequent at the 7th position of the peptide (30%). In 
contrast, in the AAV display library and the Nonbinder pool, the frequency of arginine at 
this position (15% and 9%, respectively) was equal or lower than the expectation for a 
randomized distribution (14.3%).  
Interestingly, Binder pool insertions carrying no positive amino acids displayed an 
exceptionally high amount of alanine (A), glycine (G) and serine (S) (data not shown), the 
three smallest amino acids, suggesting a reduced impact on the wild-type capsid three-
dimensional structure, which is less likely to interfere with binding of heparin.  
The Nonbinder pool showed clearly a higher presence of negative charged amino 
acids [aspartic acid (D) and glutamic acid (E)] (Table 1A, B). Moreover, although the 
number of negative residues observed in the Binder pool matched statistical expectations, 
only 2% of the clones carried a net negative charge in its insertion, while 76% carried a 
positive and 21.5% a neutral charge. In clear contrast, the Nonbinder pool consisted of 
53% negative, 8% positive and 39% neutral net charged inserts. This bias becomes even 
clearer if histidine is considered neutral due to its low pKa: Binder pool insertions would 
then be 2% negative, 64% positive and 34% neutral while Nonbinder pool consisted of 
64% negative, 2% positive and 34% neutral. These observations strongly suggest that the 
presence of negative charges is deleterious for functional binding of AAV vectors to 
negatively charged heparin/HSPG.  
Infection and uptake experiments on HeLa cells with the Binder and the Nonbinder 
pool packaged with scGFP as transgene reflected the different binding behaviour. While 
uptake of the Binder and Nonbinder pool should only show minor differences in AAV-
mediated GFP expression, the infection experiment should reveal significant differences in 
GFP expression for the Binder and the Nonbinder pool, since the Binder pool should be 
much more efficient in infecting HeLa cells, because of their ability to interact with HSPG, 
AAV's primary receptor. To analyze this, HeLa cells were infected with 1x103 genomic 
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particles per cell of the Binder/GFP, Nonbinder/GFP pool and rAAV/GFP (as control), and 
incubated for 48h. The GFP expression level was determined by FACS analysis. For the 
uptake experiments, plates were coated with the A20 antibody recognizing the intact AAV 
capsid. Unbound A20 was washed away and the plate was then incubated with rAAV/GFP, 
the Binder library or the Nonbinder library with 1x103 genomic particles per cell. After 
incubation and a washing step, HeLa cells were seeded into the plates and incubated for 
further 48h. Transduction efficiency was determined by FACS analysis. 
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 were coated with A20 and incubated with rAAV/GFP as control, the Binder or the 
GPC of 1x103). After washing of unbound virus, HeLa cells were seeded into the wells and 
S after 48h. For infection HeLa cells were seeded into wells and infected with rAAV/GFP, 
 Nonbinder pool. Cells were analyzed by FACS 48h later. 
er pool behaved similar to rAAV/GFP when infecting HeLa, both 
 to 99% transduction efficiency on HeLa, using 1x103 GPC. rAAV/GFP 
nsduction efficiency by uptake with 1x103 GPC, whereas Binder and 
showed both similar transduction efficiencies with 50 to 60%. For 
er, the Nonbinder pool showed transduction efficiency of only 20% using 
ear contrast to the Binder pool with 80% indicating that the Binder pool 
 infecting HeLa cells than the Nonbinder pool as expected.  
on experiments with heparin and the Binder and the Nonbinder pool were 
 cells were transduced with 1x103 infectious particles per cell of rAAV-
Chapter III - Application of the coupled AAV library for selection of gene therapy vectors 71
RC, Binder pool and Nonbinder pool, preincubated with heparin (25U/ml). After 48h the 
transduction efficiency was measured by FACS analysis (Figure 3).  
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petition of transduction on HeLa cells
 seeded into 24well plates. rAAV-RC, Binder pool and Nonbinder pool were preincubated 
ut heparin and the cells were transduced with 1x103 infectious particles per cell. After 48h 
lyszed by FACS for GFP expressing cells. 
-RC and Binder transduced HeLa 90 to 100% when not preincubated with 
parin competition, transduction efficiency of both rAAV-RC and Binder pool 
ked by heparin to 11% (rAAV-RC) and 2% (Binder pool), respectively. In 
e Nonbinder pool, which transduction efficiency was unaffected by the 
th heparin, transducing HeLa with 8% with or without heparin, and indicating 
inder pool is heparin independent. 
odistribution of heparin Binders and Nonbinders 
usly an AAV targeting vector was described, rAAV-MTP, that allowed 
ular targeting (White et al. 2004). Simultaneous detargeting of this vector 
d spleen was observed. This vector showed a reduced ability to bind to 
te et al. 2004). Here, it was analysed whether the inability of AAV insertion 
ind heparin directly correlates with detargeting from liver and spleen. 
nder and Nonbinder pools were produced as beta-galactosidase expressing 
AV vectors (rAAV) as previously described (Work et al. 2005). rAAV with 
sid (rAAV-RC) was used as a control. First, the ability to infect the 
r carcinoma cell line HepG2 was determined (Figure 4).  
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All three viral preparations were able to transduce HepG2. rAAV-RC and Binder 
ol showed a comparable transduction efficiency whereas the Nonbinder pool was about 
-fold less efficient as expected. Since the addition of heparin completely abolished 
AV-RC mediated transduction (data not shown), it can be assumed that AAV infection 
 this cell line depends on HSPG binding.  
Thereafter, 4 x 109 genomic particles were injected intravenously into C57/B6 mice 
=4) and biodistribution studies were performed as described (White et al. 2004). Animals 
jected with rAAV-RC and Binder pool showed a comparable biodistribution with the 
ghest vector DNA level in spleen and liver (Figure 5).  
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 Figure 5: Biodistribution of rAAV-RC, B-rAAV-pool and NB-rAAV-pool in C57/B6 mice 
4x109 genomic particles of the different vector preparations were injected into the tail vein of 12 week old 
C57/B6 mice. 24 h p.i. mice were sacrificed. DNA was extracted from blood and tissues. Vector genomes per 
tissue were quantified by PCR (Taqman). 
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In contrast, the Nonbinder rAAV-pool showed a 102- and 31.8-fold reduction of 
 DNA level in the spleen in comparison to rAAV-RC and Binder pool, respectively, 
as in the liver an 8.8- and 6.7-fold reduction was detected. In addition, elevated 
 of viral DNA in the blood were measured for the Nonbinder pool consistently with 
el of liver and spleen detargeting. 
 
ction on Hepatocytes with the Nonbinder library 
Recombinant AAV and targeting mutants within the binder pool are sequestered in 
er due to an unspecific interaction with heparin. This is not the case with targeting 
ts within the Nonbinder pool. A possible application for HSPG-independent AAV 
s lies in the therapy of hemophilia A or B (VandenDriessche and Collen et al. 2001; 
 and Collen et al. 2001). Gene therapy for hemophilia demands a selective targeting 
 liver while other organs are detargeted. In addition, a high expression level should 
ched. The Nonbinder pool consists of a pool of mutants, which have in common their 
ity to bind to heparin and therefore their inability to be unspecifically requestered in 
ver. By AAV display selection on hepatocytes, a targeting mutant should be 
able out of this pool which is able to efficiently and receptor-specifically transduce 
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hepatocytes. Besides an efficient and specific cell entry, the mutant is also selected for 
optimized intracellular processes since only if a mutant is able to reach the nucleus 
progeny production will occur during selection. For this, an AAV mutant was to be 
obtained for efficient retargeting of a primary hepatocytic cell line kindly provided by 
Thierry VandenDriessche and Marinee Khim Chuah (Leuven, Belgium).  
 
Selection procedure on Hepatocytes 
Hepatocytes were seeded into cell dishes and one day later infected with the AAV 
Nonbinder library applying a GPC of 1. Cells were incubated for two more days in the 
presence of adenovirus to allow replication and packaging of mutants that infected the 
hepatocytes.  
Four rounds of selection were performed whereas in the following rounds a GPC of 100 
was used. Viral DNA was extracted from cell lysate after each round and amplified by 
PCR. The DNA was cloned into the AAV pRC vector and the plasmids were transformed 
into bacteria. At least one hundred single clones from each round were sequenced and 
analyzed. 
Already after the second round of selection one sequence was remarkably 
outweighing all others. 
 
 I. Round II. Round III.Round IV. Round 
VGDSTRD 14.1% 97.6% ▲ 100% ▲ 100% ▲ 
GGGVSTG 68% 0%   ▼ 0%  ▼ 0%  ▼ 
TGASPRD 5.1% 0%   ▼ 0%  ▼ 0%  ▼ 
others 12.8% 2.4% ▼ 0%  ▼ 0%  ▼ 
 
Table 2: Frequency of identified sequences  
At least one hundred clones were sequenced and analyzed after round I to IV in selection of Nonbinder 
pool on hepatocytes. The amount of each selected sequence was set in relation to the total of 
sequences analyzed. 
 
 
 
The strongly selected sequence VGDSTRD was cloned into an AAV helper 
plasmid and used to package the respective recombinant AAV mutant with GFP as 
transgene (HepIV) for transduction experiments.  
Transduction experiments are currently carried out in our group in Cologne and in 
collaboration with the group of Thierry VandenDriessche in Leuven. 
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4.3. Discussion and Outlook 
AAV Library can be divided into heparin/HSPG binders and Nonbinders 
with specific binding properties  
The insertion of a peptide sequence into position 587 of the AAV capsid interferes 
with the binding site for the primary receptor of AAV, the heparan sulphate proteoglycan 
(HSPG) (Perabo et al. 2003). However, the binding to HSPG is only ablated in some 
mutants of the AAV library, not in all. Based on our hypothesis that peptides containing a 
net negative charge are prone to confer a HSPG non-binding phenotype and that a net 
positive charge can contribute to a restored heparin binding site, the coupled library was 
separated into a Binder and a Nonbinder pool. 
This was done by a heparin column. The flow through was considered as 
Nonbinder pool and the eluted fraction as Binder pool. Clones from both fractions were 
then sequenced and analyzed as done for the libraries coupled through uptake and 
infection. Small amino acids seemed to be preferred. In the Binder pool a clear prevalence 
for the positively charged amino acid arginine was found and strikingly arginine mostly 
occurred in amino acid position 7 of the inserted sequence. The proximity of R588 to the 
last position of the inserted peptide could facilitate reconstitution of a functional motif if an 
arginine is present at this latter position. Insertion of positively charged peptides could lead 
to a HSPG binding phenotype by reconstituting a binding motif in combination with one of 
the original arginines or independently from them (compare Chapter II, Figure 12) 
explaining the good transduction efficiency, compared to rAAV/GFP, in the infection 
experiment described below (compare Figure 3). In contrast, the Nonbinder pool, showed 
clearly a higher frequency of negatively charged amino acids, especially of aspartic acid 
and glutamic acid. These observations strongly suggest that the presence of negative 
charges is deleterious for functional binding of AAV vectors to negatively charged 
heparin/HSPG.  
To reflect the binding properties of the Binder and the Nonbinder pool, both 
libraries were packaged with scGFP as transgene and submitted to infection and uptake 
experiments on HeLa cells, expecting that the Binder pool would show higher binding 
affinity to HSPG and therefore higher transduction efficiencies. This experiment clearly 
demonstrated that, as expected with uptake, no major difference in the transduction 
efficiency of Binders and Nonbinders could be seen, but the Binders were clearly more 
potent in infecting HeLa cells than the Nonbinders, which underlines that the HSPG 
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binding plays a major role in AAV infection. Heparin competition experiments emphasized 
that the Nonbinder pool transduces cells independent from HSPG and that it provides clear 
advantages for selection of a real retargeting mutant since the natural HSPG binding 
phenotype is ablated. 
 
In vivo biodistribution of Binder and Nonbinder pool 
Biodistribution studies with wildtype AAV2 showed that vector genomes were 
predominantly found in liver and spleen after tail vein injections in mice (Nathwani et al. 
2001). Efforts have been made to identify receptor molecules on the cellular surface 
responsible for transduction of a certain cell type. For AAV-2, heparan sulphate 
proteoglycan (HSPG) has been shown to act as a primary receptor, next to its secondary 
receptors, αVβ5 integrin, human fibroblast growth factor receptor I (FGFR) and the 
hepatocyte growth factor receptor (HGFR). (Summerford and Samulski 1998; Summerford 
et al. 1999; Qing et al. 1999; Kashiwakura et al. 2005). Systematic deletions of potential 
heparin-binding motifs on the AAV capsid indicated that heparin binding is a prerequisite 
for efficient transduction of liver, but not kidney, heart or lung tissue (Kern et al. 2003).  
In this study a heparin Binder and Nonbinder pool of the AAV library were isolated 
by heparin column chromatography and tested for their ability to transduce HepG2 cells, a 
hepatocellular carcinoma cell line. Producing recombinant AAV from both libraries and 
using a vector with a wild-type capsid (rAAV-RC) as control, all three viral preparations 
were able to transduce HepG2. rAAV-RC and Binder pool showed comparable 
transduction efficiencies. Since the addition of heparin completely abolished rAAV-RC 
mediated transduction (data not shown), it can be assumed that AAV infection of this cell 
line depends on HSPG binding. The mutants within the Nonbinder pool were unable to 
bind to HSPG. This suggests that capsid variants of the Nonbinder pool are able to 
transduce HepG2 cells by other means than HSPG binding, pointing towards new and 
specific ligand-receptor interactions. 
C57/B6 mice were injected with rAAV-RC, Binder pool and the Nonbinder pool and 
analyzed for distribution of the vectors in the mouse organs. Thereby animals injected with 
rAAV-RC and Binder pool showed a comparable biodistribution with the highest vector 
DNA levels seen in spleen and liver. 
In contrast, the Nonbinder pool showed a 102- and 31.8-fold reduction in vector 
DNA level in the spleen in comparison to rAAV-RC and Binder pool, respectively, 
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whereas in the liver an 8.8- and 6.7-fold reduction was detected. In addition, elevated 
levels of viral DNA in the blood were measured for the Nonbinder pool being consistent 
with the level of liver and spleen detargeting. This suggests an unspecific HSPG-dependent 
retention of rAAV and HSPG-binding of rAAV-targeting vectors in liver and spleen on the 
one hand and an HSPG-independent infection of cells in the liver mediated by some 
peptide insertions of the Nonbinder pool on the other hand. This hypothesis is in agreement 
with results previously obtained for a HSPG-knock-out mutant (Kern et al. 2003) and 
explains the liver and spleen detargeting observed for rAAV-MTP (White et al. 2004).  
Furthermore, our studies revealed different ways by which an inserted peptide is 
able to confer HSPG-binding abilities to AAV targeting vectors (compare Chapter II, 
Figure 12) and may help to fine tune the peptide insertion in order to ablate HSPG binding 
and to obtain tissue specific vectors. This knowledge could also improve targeting mutants 
where R585 and/or R588 are substituted by other amino acids, since even in this case, 
some peptides (Chapter II, Figure 12G) would restore HSPG binding. 
 
Nonbinder library allows the selection of heparin/HSPG-independent 
targeting mutants on Hepatocytes  
To underline the advantages of a Nonbinder library for selection of heparin 
independent retargeting mutants, a selection on primary Hepatocytes was performed with 
the Nonbinder library. Heparin binding mutants and, therefore, mutants with the natural 
tropism were excluded from the selection in the first place. Four selection rounds were 
performed on Hepatocytes, starting with a strong selection pressure of one genomic 
particle per cell in the first round of selection. The mutant which became prominent 
already after the second round of selection on Hepatocytes, with the insertion sequence 
VGDSTRD, was cloned into the pRC AAV vector and packaged with self complementary 
GFP (scGFP) as transgene (HepIV). For rAAV packaged with scGFP higher transduction 
efficiencies were expected, since the self complementary transgene can bypass the rate-
limiting step of second-strand synthesis (McCarty et al. 2001). This vector is now analyzed 
in comparison to recombinant AAV with unmodified capsid for its efficiency in vitro and 
in vivo. 
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Outlook 
An optimally designed gene therapy vector is able to find and transduce only its 
target tissue after intravenous injection of this vector (systemic application). With 
recombinant AAV carrying wildtype capsids, most of the virus is filtrated from the blood 
by the liver, based on its interaction with HSPG, before the virus has even a chance to find 
the target tissue of choice. In addition, binding to HSPG expressing cells outside the liver 
like endothelia cells of the vessels will sequester AAV. Ideally, the targeting variant will 
only transduce the target tissue whereas no other tissues are affected. Retargeting of AAV 
vectors to the liver by means of specific but HSPG independent transduction of 
Hepatocytes makes sense for gene therapy applications where i) the transgene has to be 
solely expressed in the liver and ii) the transfer vector has to be optimized for efficient 
transgene expression. One example for such a gene therapy application is the delivery of 
Factor VIII and Factor IX for the treatment of hemophilia A and B patients, as it was 
shown that the highest expression levels of the blot clotting factors was achieved in cases 
where the rAAV vector was injected directly into the liver (compared to e.g. salvary 
glands, or muscle transduction) (VandenDriessche and Collen 2001). To make a 
hemophilia gene therapy more convenient for both, the patient and the physician, systemic 
application of gene therapy vectors encoding for Factor VIII and Factor IX finding only 
their target –the hepatocytes of the liver- by themselves, will be desirable. 
Further experiments have to prove that the selected mutant HepIV results in a better 
transduction efficiency on hepatocytes and shows HSPG independent behaviour at the 
same time. In vivo biodistribution studies have to show the advantage of HepIV in 
comparison to wtAAV. For the selection of new mutants the selection pressure can be 
tightened by a negative selection round on HeLa cells, where the supernatant with non-
infectious virions will be used for selection on Hepatocytes, further reinforcing the 
selection cell-specific mutants (targeting mutants which are able to infect HeLa cells 
independent of HSPG will be lost in this process). 
. 
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5. Material and Methods 
5.1. Material 
Cell lines 
Hek 293 
Cell type:   human embryonic kidney cells 
Medium:   DMEM with GlutaMAX1 (Invitrogen) + 10% FCS + 1% P/S 
Origin:   AG Hallek, Gene Center LMU München 
 
HeLa 
Cell type:   human cervix carcinoma cell line 
Medium:   DMEM with GlutaMAX1 (Invitrogen) + 10% FCS + 1% P/S  
Origin:   AG Hallek, Gene Center LMU München 
 
Hepatocytes 
Cell type:   human primary hepatocytes 
Medium:   DMEM with GlutaMAX1 (Invitrogen) + 10% FCS + 1% P/S 
Origin:   provided by Thierry Vandendriessche, Leuven, Belgium 
 
HT29 
Cell type:   epithelial colon carcinoma 
Medium:   RPMI (Invitrogen) + 10% FCS + 1% P/S 
Origin:   ATCC cell bank 
 
SVEC 
Cell type:   SV40-transformed axillary lymph node endothelia 
Medium:   DMEM (Invitrogen) + 10% FCS + 1% P/S 
Origin:   ATCC cell bank 
 
 
 
 
Material and Methods 80 
MCF-7 
Cell type:   epithelial mammary gland adenocarcinoma 
Medium:   MEM + 10% FCS + 1% P/S 
Origin:   provided by Hauke Lilie, Halle 
 
Viruses and vectors 
wtAAV 
The recombinant AAV with unmodified capsid with GFP transgene will in the following 
be termed as rAAV/GFP. rAAV/GFP was packaged in 293 cells as described below. 
 
Recombinant AAV 
The modification and use of the rAAV vectors are described in the respective chapters. All 
rAAVs were packaged in 293 cells and purified by Iodixanol step gradient if not stated 
otherwise. 
 
Wt-adenovirus was generated with the plasmid pG3602 and propagated in HeLa cells. 
 
Bacteria 
The used plasmids were amplified in E. coli TOP10F' and E. coli DH10B bacteria. For 
electroporation XL-1 Blue MRF were used. 
 
TOP10F’: 
F' {lacIqTn10(TetR)} mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 
araD139 ∆ (ara-leu)7697 galU galK rpsL endA1 nupG  
(Invitrogen Corp., Karlsruhe) 
 
DH10B: 
F' mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74 recA1 end A1 araD139 ∆ (ara-
leu)7697 galU galK λ-rpsL nupG  
(Invitrogen Corp., Karlsruhe) 
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XL-1 blue MRF 
∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F´ 
proAB lacIqZ ∆M15Tn10 (Tetr)]. 
(Stratagene, USA) 
 
Plasmids 
pRC, pRC99, pRC-Kotin and pGFP were provided by AG Hallek, Gene Center. pXX6-80 
was kindly made available by Prof. Jude Samulski (Chapel Hill, University of North 
Carolina, USA).  
 
pGFP 
The pGFP plasmid is an AAV-based vector plasmid in which the AAV ITR sequences are 
flanking the hygromycin selectable marker gene controlled by the thymidine kinase 
promoter and the Aequorea victoria Green Fluorescence Protein (GFP) gene regulated by 
the cytomegalovirus promoter. pGFP was generated by inserting the Asp718-Not I 
fragment of pEGFP-N1 (Clontech) into the Asp718-Not I sites of psub/CEP4 (Sal invers). 
psub/Cep4 (Sal invers) is a derivative of psub201(+) (Samulski et al. 1987), which was 
digested with Xba I, blunt ended and ligated to blunt ended 3923 bp Sal I-Nru I-Fragment 
of pCEP4 (Sal inverse). pCEP4 (Sal inverse) differs from pCEP4 (Invitrogen) by inversion 
of the Sal I (8)-Sal I (1316)-fragment.  
 
pRC 
The pRC plasmid was constructed as previously described (Girod et al. 1999). Briefly, the 
4.5 kb Xba I-fragment of psub201(+) (Samulski et al. 1987), containing the rep and cap 
ORFs of AAV was subcloned into the Pst I and BamH I sites of pSV40oriAAV (Chiorini 
et al. 1995). 
 
pRC99 
Variant of pRC containing a multiple cloning site in position 587, cleavable by AscI and 
MluI. 
 
P587Lib7 
AAV library plasmid, generated as described in Perabo et al. 2003 
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pRC-Kotin 
pRC lacking ITRs with an additional single cleaving site for SnaBI. 
 
pXX6-80 
Adeno-Helperplasmid: Expression plasmid for the adenoviral proteins VA, E2A und E4, 
which are needed for packaging of AAV next to E1a und E1b. 
 
Enzymes 
Benzonase       Merck, Darmstadt 
Proteinase K       Sigma, Deisenhofen 
All restriction enzymes were obtained by New England Biolabs, Schwalbach 
Antibodies 
A20 (AAV2-capsid antibody)    DKFZ Heidelberg,  
Arbeitsgruppe Prof. Dr. J. 
Kleinschmidt 
B1 (AAV VP-specific Antibody)    DKFZ Heidelberg,  
Arbeitsgruppe Prof. Dr. J. 
Kleinschmidt 
B3 (Lewis)-antibody       University of Halle, Hauke Lilie 
Omalizumab (Xolair
®
)     Novartis, Germany 
Mouse IgG1 Isotype Control     R&D Systems, Germany 
Monoclonal Antibody to CETP    Acris Antibodies,  
         Hiddenhausen 
Synthetic Oligonucleotides 
All synthetic oligonucleotides were obtained by Metabion in Martinried. 
 
Chemicals and other Material 
Agarose  Sigma, Deisenhofen 
Ampicillin Sigma, Deisenhofen 
Benzonase Merck, Darmstadt 
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Biomax Light Film Kodak, Stuttgart 
Blocking-Reagenz Boehringer Mannheim Boehringer, Mannheim 
DIG-DNS Labeling and Detection Kit Boehringer, Mannheim 
DMEM mit GlutaMAX1 Invitrogen Corporation, Karls-
ruhe 
DMSO (Dimethylsulfoxid) Merck, Darmstadt 
EDTA AppliChem, Darmstadt 
Ethidiumbromid Roth, Karlsruhe 
Formamid Fluka ChemieAG, Buchs, 
Schweiz 
FCS (Fetal Calf Serum) Invitrogen Corporation, Karls-
ruhe 
HEPES Roth, Karlsruhe 
λ DNA Hind III   New England Biolabs, 
  Schwalbach 
Molecular Weight Marker for 1kb  New England Biolabs, 
Schwalbach 
Molecular Weight Marker λ Hind III   New England Biolabs,   
     Schwalbach 
Nylonmembran Roche, Mannheim 
OptiPrepTM (Iodixanol) Sigma, Deisenhofen 
PBS  Invitrogen Corporation, Karls-
ruhe 
Primer  Metabion, Martinsried 
Restriktion enzymes  New England Biolabs, Schwal-
bach 
RPMI 1640 mit GlutaMAX1  Invitrogen Corporation, Karls-
ruhe 
SDS (Natriumdodecylsulfat)  Merck, Darmstadt  
SSC (Salines Sodium Citrate)  Merck, Darmstadt 
Tris  Merck, Darmstadt 
Trypsin-EDTA  Invitrogen Corporation, Karls-
ruhe 
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Primers 
4066 BACK  
5'- ATG TCC GTC CGT GTG TGG -3' 
 
3201 FOR 
5'- GGT ACG ACG ACG ATT GCC -3' 
 
BsiW back 
5'- TAC CAG CTC CCG TAC GTC CTC GGC -3' 
 
New SnaBI 1 
5'- CGC CAT GCT ACT TAT CTA CG -3' 
 
New SnaBI 2 
5'- AA GAT TAA CCC GCC ATC C -3' 
 
For the PCR cloning of the AAV Cys mutants, pRC backbone and the following primers 
were used: 
Outer primer: 4066Back and 3201For 
Inner primer: 
S452C For  5'-AACACTCCATGCGGAACCA-3' 
S452C Back  5'-GTGGTTCCGCATGGAGTGT-3' 
 
G453C For  5'-CACTCCAAGTTGCACCACCA-3' 
G453C Back  5'-TGGTGGTGCAACTTGGAGTG-3' 
 
N587C For  5'-CAGAGAGGCTGCAGACAAG-3' 
N587C Back  5'-GCTTGTCTGCAGCCTCTCT-3' 
The mutants G265C, S384C, and A667C were cloned by Florian Kreppel in Ulm. 
 
Standards and Kits 
DNeasy®Tissue Kit Qiagen, Hilden 
EndoFree® Plasmid Kits Qiagen, Hilden 
PCR Purification Kit    Qiagen, Hilden 
Gel Extraction Kit  Qiagen, Hilden 
Light-Cycler-FastStart DNA Master SYBR Green I Roche, Mannheim 
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Buffer and Solutions 
 
Ampicillin: Stock Solution: 50 mg/ml in H2O, sterile filtered 
 Used concentration: 50 µg/ml 
    
EB-Puffer: Tris/HCl, pH 8.0 10 mM 
 
10x TBE: Tris 890 mM 
 Boric Acid 890 mM 
 EDTA 20 mM 
 
Freeze Medium: FCS      50   % 
 DMEM      40   % 
 DMSO      10   % 
 
    
15 % Iodixanol-Solution 1x PBS 10  % 
 MgCl2 1 mM 
 KCl 2.5 mM 
 NaCl 1 M 
 Optiprep 15 % 
 Phenolrot 0.075 % 
 H2O ad 500 ml 
    
25 % Iodixanol-Solution 1x PBS 10 % 
 MgCl2 1 mM 
 KCl 2.5 mM 
 Optiprep 25 % 
 Phenolrot 0.01 % 
 H2O ad 500 ml 
    
40 % Iodixanol-Solution 1x PBS 10 % 
 MgCl2 1 mM 
 KCl 2.5 mM 
 Optiprep 40 % 
 H2O ad 500 ml 
    
60 % Iodixanol-Solution MgCl2 1 mM 
 KCl 2.5 mM 
 Optiprep 60 % 
 Phenolrot 0.025 % 
 H2O ad 500 ml 
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Loading buffer Agarosegel Glycerin 50 % 
 EDTA, pH 8.0 100 mM 
 Bromphenolblau 0.25 % 
 Xylencyanol FF 0.25 % 
    
Loading buffer SDS gel Tris/HCl pH 6.8 200 mM 
 Glycerol 25 % 
 SDS 5 % 
 Bromphenolblau 0.025 % 
 β-Mercapto EtOH 0,5 M 
 
 
LB-Medium: Bacto Trypton 1 % 
 Yeast Extract 0.5 % 
 NaCl 0.5 % 
 NaOH 1 mM 
 Bacto Agar (bei Platten) 1.5 % 
    
   
Lysis buffer  NaCl         150   mM 
 Tris/HCl, pH 8.5           50   mM 
 
 
Transfection buffer (HBS) for 
Virus production: 
 
HEPES, pH 7.2 
  
50 
 
mM 
 NaCl 280 mM 
 Na3P 1.5 mM 
    
 CaCl2-solution CaCl2
 
250 mM 
10xTBS Tris pH8.0 100 mM 
 NaCl 1.5 M 
    
    
TBST TBS 100 ml 
 Tween20 0.5 ml 
 ad H2O 1000 ml 
Material and Methods 87
Equipment 
For the equipment used, please refer to the corresponding chapters. 
 
 
5.2. Methods 
General Methods 
Cultivation of Microorganism (Bacteria) 
Cultivation on Agar plates 
Bacteria were plated onto a sterile LB-agar plate with a sterile Drygalski-spatula and 
cultivated over night at 37°C.  
For production of agar plates, LB medium was poured after sterilization by autoclave into 
sterile Petri plates and left for cooling. Plates were kept at 4°C. 
For selection of plasmids the corresponding antibiotic was put into the medium before 
pouring the plates. 
 
Liquid bacteria culture 
Single bacteria colonies were cultivated in 5ml LB-medium and the corresponding 
antibiotic over night at 37°C and 220 rpm. Over night cultures were then used for 
inoculation of larger cultures or used for Mini preps. 
 
Preparation and analysis of nucleid acids 
Isolation of plasmids from bacteria 
Isolation by QIAGEN Mini Prep Kit 
Plasmids for sequencing were prepared and purified by QIAGEN Mini Prep Kit using the 
Mini prep protocol using a microcentrifuge. 
Endotoxin-free isolation by QIAGEN Mega prep kit 
Plasmids for packaging of wtAAV and rAAV were prepared and purified by QIAGEN 
EndoFree Mega Kit using the QIAGEN EndoFree Plasmid Mega protocol. 
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Isolation of DNA from cells with QIAGEN DNeasy Tissue Kit 
DNA from cell lysates was extracted and isolated using the QIAGEN DNeasy Tissue Kit. 
The kit was applied as described in the protocol for cultured from animal cells. 
 
Separation of DNA by electrophoresis in agarose gel 
For preparative separation and control of DNA size after digest with restriction enzymes, 
DNA and DNA fragments were separated in agarose gel by electrophoresis. 
For this 0.5 - 1% agarose was heated in Tris-Borat-EDTA- (TBE; 89mM Tris, 89mM boric 
acid, 2mM EDTA) buffer and ethidium bromide was added for detection of DNA. The hot 
gel was poured into the gel chamber and left for cooling. 0.1 volumes of loading buffer 
was added to the DNA samples and the samples were put onto the gel in TBE buffer and 
run at 60 – 120 Volt. DNA was made visible by UV absorption of ethidium bromide at 
366nm. For determination of DNA fragment size a DNA marker was run with the samples. 
 
Isolation and purification of DNA with QIAquick Gel Extraction Kit 
For isolation and purification of DNA from agarose gels the QIAquick Gel Extraction Kit 
was applied. DNA was prepared using the QIAquick Gel Extraction Kit protocol using a 
microcentrifuge. 
 
Purification of DNA by QIAGEN PCR Purification Kit 
For purification of DNA from enzymatic reactions the QIAquick PCR Purification Kit was 
applied using the QIAquick PCR Purification Kit protocol using a microcentrifuge. 
 
Determination of DNA concentration 
Nucleid acid concentrations were determined by photometer analysis and evaluated by 
computer. The ratio of OD260/OD280 determines the purity of DNA with ratio of 1.8-2.0 
for good purity. Ratios below 1.8 point to contaminations through protein. 
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Enzymatic reactions with plasmids and DNA-fragments 
Digestion of DNA with restriction enzymes 
The cleavage of DNA with restriction enzymes was used for vector cloning and for control 
cleavage of the obtained insertions or deletions. For complete cleavage 0.2 to 10 µg DNA 
were used with 1 to 30 U enzyme. DNA was incubated for 1.5 – 2 h at the given 
temperature in 20 to 50 µl volume. The necessary conditions like restriction buffer, 
temperature and restriction activity was obtained by the manufacture's manual and adapted. 
Cleavage was controlled by agarose gel analysis. 
 
Dephosphorylation with alkaline phosphatase 
To avoid intra molecular religation of linearised vector plasmids during cloning, the 5'- 
phosphoric acid was cleaved by alkaline phosphatase (CIP). After restriction cleavage 1 µl 
of Calf Intestinal Phosphatase (CIP) was added to a total volume to 50 µl sample and 
incubated at 37°C for 30 min. For further reactions CIP was then removed by DNA 
purification with the QIAGEN PCR Purification Kit.  
 
Ligation of DNA-fragments 
T4-DNA-Ligase was used for cloning of DNA fragments and plasmids. Usually 100 -200 
ng dephosphorylated plasmid backbone was ligated with 3 to 5 times more molar insert. 
Ligation was carried out in a total volume of 20 µl with ligase buffer and 10 U T4-Ligase. 
Ligation was incubated at 16°C over night or at room temperature for 2 h. After ligation 
the ligase was inactivated by incubation at 65°C for 10min and the DNA was submitted to 
dialysis for 3 h and then transformed into electro competent bacteria. As negative control a 
CIP treated plasmid backbone incubated without the insert was used. 
 
Electroporation of bacteria 
Ligated plasmids were transformed into bacteria by electroporation. 5µl of ligated DNA 
was mixed with 40µl MRF XL-1 Blue bacteria and submitted to BioRad cuvettes. 
Electroporation conditions were set to 1.85kb (600Ohm) and the electroporated DNA was 
then diluted in 1ml LB medium without antibiotics and submitted to shaking at 37°C for 
1h. After that the bacteria containing medium was diluted 1:1000 and distributed onto agar 
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plates containing Ampicillin. Plates were controlled for colonies the next day after 
incubation at 37°C over night. 
 
DNA-Sequencing 
Sequence analyses for control of cloned plasmids were carried out by Laboratory for 
Functional Genome Analysis (LaFuga) in the Gene Center. Sequence analysis for the 
single insertion sequences obtained in the selection procedure was carried out by 
AGOWA, Berlin. For this, single bacteria colonies were picked and resuspended in 96well 
plate in 100µl LB medium and sent to the AGOWA. 
 
Cultivation of cell lines 
Cell Culture  
All cell lines mentioned in Material were kept at 37°C and 5% CO2 in the respective 
medium. All cell lines used were adherent cells and were kept as "monolayer"-cultures in 
plastic cell culture vessels (TPP). Cells were splitted with Trypsin after washing with PBS 
and medium was changed at least every three days. 
 
Cell stocks 
About 107 cells were suspended in cold freeze medium, distributed in 1ml Cryo-tubes 
(Nunc) and cooled on ice for at least one hour. Stocks were then cooled in the -80°C 
freezer and later stored in liquid nitrogen. 
For recultivation Cryo-tubes were thawed in warm water and cells were quickly suspended 
in the according medium. Medium was changed after one day to remove remainders of 
DMSO. 
 
Adenovirus-free Production of AAV vector particles and purification by 
Iodixanol density gradient 
The packaging and purification of AAV vectors were carried out under the laminar flow 
and only sterile buffers were used. 
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Cells for packaging 
For packaging HEK 293 cells were used in 15cm2 cell culture plates, 15 plates for one 
produced vector. 24h before transfection 7.5x106 293 cells were seeded into plates.  
 
Transfection 
The medium was changed 3hs before transfection. The transfection was carried out in 
Ca3(PO4)2 medium at 70% confluent cells. For each plate a solution of 1ml 250mMCaCl2 
with 7.5µg helperplasmid (e.g. pGFP as transgene), 7.5µg vector plasmid (e.g. pRC for 
packaging of AAV with wt capsid) and 22.5µg Adeno-helper plasmid pXX6-80 was 
prepared and 1ml transfection buffer HBS was added (for packaging of the AAV library 
15µg of library plasmids were transfected with 22,5µg pXX6-80). The solution was 
incubated for 2min at room temperature and then pipetted onto the plate while cautious 
mixing with the medium. Cells were incubated for 24h at 37°C and 5%CO2 and then the 
medium was changed to DMEM with 2% FCS and cells were kept for another 24h before 
harvesting.  
 
Harvest of virus producing cells 
293 cells were harvested with a cell lifter, transferred into GSA tubes and centrifuged at 
3000g and 4°C for 10min. The cell pellet was resuspended in 2.5 ml lysis buffer and 
objected to three rounds of freeze and thaw cycles. Cells were again pelleted by 
centrifugation and the supernatant was used for further purification.  
 
Purification of AAV vectors by Iodixanol density gradient 
The supernatant after cell lysis was centrifuged again for greater purity in SS34 tubes and 
then transferred to ultra centrifugation tubes (26x77mm, Beckman). Iodixanol solutions of 
different concentrations were layered beneath the virus containing solution. By this an 
Iodixanol gradient was created, with 6ml 60% on the bottom, 5ml 40%, 6ml 25% and 9ml 
15% going upwards and the virus solution on top. The gradient was centrifuged in an ultra 
centrifuge at 65.000rpm for 1.5h and at 18°C. The 40% phase was then extracted with a 
cannula by puncturing the tube underneath the 40% phase and allowing the solution to drip 
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into a Falcon tube until the 25% phase was reached. Genomic and capsid titers were then 
determined for experiments or the 40% phase was objected to further purification by gel 
filtration when necessary.  
Evaluation of AAV titers 
Evaluation of AAV genomic titers Dot Blot 
For determination of the genomic titer, the virus samples were digested with proteinase K 
(Merck). For this 2 to 10µl of virus sample were added to 95µl PK buffer (75mM Tris 
pH8.0, 25mM EDTA) and ad 180.5µl PBS. The sample was incubated at 70°C for 10min 
and 9.5µl proteinase K was added and incubated at 50°C. After 2h 10µl NaOH were added 
and the samples were diluted in a 96well plate 1:2 and incubated for 1h at 37°C. Samples 
were blotted to nylone membrane using a Dot Blot apparature. The membrane was cross-
linked by incubation at 80°C for 2h or 15min at 120°C. The membrane was treated with 
SDS-hybridization solution for 15min at 42°C and then incubated with SDS-hybridization 
solution plus the DNA probe (the labeling of the DNA probes was conducted as 
recommended by the manufacturer in the standard protocol of the DIG DNA labeling kit 
(Roche, Mannheim)) over night at 42°C. The membrane is washed and then incubated with 
blocking buffer (blocking reagent in maleic acid) for 30min at room temperature. The 
blocking buffer is exchanged with 1.5µl anti-DIG antibody (Roche) in blocking buffer and 
incubated for 1h at room temperature. The membrane is washed again and the signals are 
detected by incubation of the membrane in detection buffer (100mM Tris pH9.5 and 
100mM NaCl) and CSPD for 20min at 37°C. The membrane is exposed to film and signals 
are visible on the developed film and compared to the according standard. 
Evaluation of AAV genomic titers by Light Cycler PCR 
For determination of genomic titers 50µl of virus solution were used for isolation of viral 
DNA by DNeasy Tissue Kit. DNA was eluted in 200µl Tris/pH 7.5, differing from the 
DNeasy Tissue Kit protocol. 2µl viral DNA were applied to the Light Cycler PCR Master 
Mix using the Light Cycler FastStart DNA Master SYBR Green I Kit. Primers were used 
according to the vector preparation (GFP-primer for GFP transgene and 
4066Back/3201For-primer for the AAV library). Titers were determined by computer 
evaluation using the program provided with the Roche Light Cycler 2.0 and compared to 
an according standard.  
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Evaluation of AAV capsid titers by A20 ELISA 
For determination of capsid titers 10 to 20µl of virus solution were coated to 96-well plates 
in serial dilution at 4°C over night. Wells were then washed and blocked with 3% BSA/5% 
Saccharose/0.05% Tween20 blocking buffer for 2h at room temperature. Bound virions 
were incubated with 50µl of the AAV recognizing antibody A20, derived from hybridom 
supernatant (kindly provided by the group of Jürgen Kleinschmidt) for 1h at room 
temperature. Wells were washed 3x with PBS/0.05% Tween20 and A20 was incubated 
with anti-mouse IgG-Biotin (Dianova, 1:50000) for 1h at room temperature. Wells were 
washed again and incubated with Streptavidin-POD antibody (Dianova, 1:1000) for 1h  at 
room temperature and quantified by an enzymatic reaction (Tetramethylbenzidin (TMB) in 
100µl DMSO and 10ml 0.1M NaOAc pH6.2 and 1µl H2O2 30%). OD was determined by 
an ELISA reader and the titers were calculated using Origin 6.0, compared to an according 
standard. 
 
Established Methods  
Conjugation of AAV-Glu and SIG peptide 
The conjugation of AAV-Glu to the SIG peptide was performed in 0.02M Tris/HCl (pH 
7.4)/ 200mM NaCl/ 5% Glycerol/ 1mM CaCl2/ 1.6mM GSSG/ 0.4mM GSH. The SIG 
peptide, designed with and without a linker region, was incubated with AAV-Glu at a 10-
fold molar excess for 5h at 10°C. After coupling the reaction mixture was dialyzed against 
ice cold PBS over night in Slide-A-Lyzer cassettes (Pierce). The genomic titers were 
determined by Dot Blot. 
 
Conjugation of AAV-Glu and B3 (Lewis)-antibody using DTP 
For conjugation with the B3 (Lewis)-antibody AAV-Glu was purified by anion exchange 
chromatography and eluted in the reaction buffer (25mM Na2HPO4/ 25mM KH2PO4 
(pH8)/ 2mM EDTA/ 0.5M NaCl) and dialyzed against the same buffer without NaCl. B3-
antibody was also dialyzed against 25mM Na2HPO4/ 25mM KH2PO4 (pH8)/ 2mM 
EDTA and both were incubated with 1mM GSH for 2h. Both proteins were shifted to pH 
5.0 by addition of buffer with pH 4.5 and dialyzed over night against 25mM Na2PO4/ 
25mM KH2PO4 (pH 4.5)/ 2mM EDTA. The pH was shifted back to pH 8.0 by addition of 
buffer pH 8.0. B3-antibody was then incubated with 10-fold molar excess of Dithiopyridin 
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(DTP) for 1h at pH 8.0. Excess DTP was removed by dialysis against the buffer. For 
conjugation AAV-Glu and the activated B3-antibody were incubated at a molar ratio of 1:1 
for 4h at 20°C. Uncoupled and coupled AAV-Glu was separated by gefiltration and eluted 
in PBS. Fractions were collected, genomic titers determined by Dot Blot and tested for 
transduction efficiency on MCF-7 cells. 
 
Transduction experiments Chapter I 
For testing if coupling was successful, the coupled vectors were submitted to transduction 
experiments. AAV-Glu coupled with SIG peptide was tested on SVEC and AAV-Glu 
coupled to B3-antibody was tested on MCF-7 cells.  
The respective cells were seeded into 24 well plates, 1x105 or 2x105 in 1ml of medium. 
Cells were rested for 24h and then counted. According to the cell number, the respective 
genomic particles per cell were used for transduction after medium change. Cells were 
incubated for 48h at 37°C and then washed once with PBS and harvested by Trypsin 
detachment. After pelleting the cells were washed again and then resuspended in 500µl 
PBS. GFP expression was determined in FACS analysis. 
 
Conjugation with Oregon Green 
For conjugation with Oregon Green (Molecular Probes), the protocol for Thiol-Reactive 
Probes from the Molecular Probes handbook was used. Briefly the vector was purified by 
gel filtration and eluted with PBS. 10-fold molar excess of reducing agent TCEP was 
added and then incubated with 10-fold molar excess of the Oregon Green dye for 2h at 
room temperature in the dark. Excess dye was removed by dialysis against PBS using 
Slide-A-Lyzer cassettes.  
 
Western Blot 
Proteins were separated in a reducing SDS gel, consisting of a 4% Polyacrylamide (PAA) 
gel and a 10% PAA separation gel. Loading buffer (Fermentas) with β–MercaptoEtOH 
was added to the samples and heated at 95°C for 5min for denaturation of the proteins. 
Rainbow Marker (Amersham Biosciences) was used as marker. The gel was run at 20mA. 
The proteins were then transferred to a nitrocellulose membrane (Protan) in a semi-dry 
transfer chamber.  
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For detection of AAV VP proteins, the membrane was developed with B1 antibody. In 
detail, the membrane was blocked with 0.2% I-Block in TBST for 1h at room temperature 
and then incubated with B1 antibody 1:20 in blocking buffer. The membrane was washed 
3x with TBST and then incubated with anti-mouse IgG-Peroxidase (Sigma) 1:5000 in 
blocking buffer at room temperature for 1h. The membrane was washed 3x in TBST and 
1x in H2O and then developed using the Super Signal West Pico developing solution by 
Pierce. The membrane was wrapped in transparent foil and the signal was detected by 
Kodak film and developed in the dark room. 
Silver Staining 
For detection of proteins by silver staining, the proteins were separated in a reducing SDS 
gel as described above. The gel was fixed in a solution of 250ml EtOH, 60ml acetic acid, 
and 250µl formaldehyde 37% ad 500ml H2O for 1h. The gel was washed 3x in 50% EtOH 
for 20min and then pretreated for 5-10sec in 500ml H2O with 0.1g Na-thiosulphate. The 
gel was again washed 3x in H2O for 20min and then stained in freshly produced 100ml 
H2O with 0.2g AgNO3 and 73µl formaldehyde 37% for 10min. The gel was washed in 
H2O for 10sec and the developed in 100ml H2O containing 0.4mg Na-thiosulphate, 50µl 
formaldehyde 37%, and 6g Na-carbonate till protein bands were visible. The development 
was stopped by 250ml EtOH and 60ml acetic acid ad 500ml H2O for 10min. and then 
dried and conserved.  
 
Transduction experiments Chapter II 
The titers of the applied vectors were determined by Light Cycler PCR (genomic titer) or 
by A20 ELISA (capsid titer). For transduction, cells were seeded into cell culture plates 
(TPP), 4x105 cells in 24 wells in 1ml of medium. Cells were rested for 24h and infected 
after the medium was changed. For the amount of vector please refer to the corresponding 
chapters. Usually genomic particles per cells (GPC) were used. Cells were incubated for 
48h at 37°C.  
For uptake the wells were coated with 100µl A20 antibody (hybridoma supernatant) and 
incubated for 1h at room temperature or at 4°C over night. Wells were washed twice with 
300µl PBS and then incubated with blocking solution (Milk Powder 1%/Tween20 1%) for 
2h. The vector was diluted in 200µl blocking solution and incubated for at least 1h at room 
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temperature. Wells were washed with 500µl PBS/1%Tween20 at least 15x. HeLa cells 
were seeded into the wells in 1ml medium and incubated for 48h at 37°C. 
Cells were washed once with PBS and then harvested by Trypsin (200µl/well) detachment. 
The cells were washed again with PBS and then resuspended in 500µl PBS for FACS 
analysis (Facscalibur, Beckman).  
Uptake and infection experiments 
For uptake and infection experiments, as well as for the selections, 15cm2 cell culture 
plates (TPP) were used. The genomic titer of the AAV library was determined by Light 
Cycler PCR.  
For infection 2x106 HeLa cells were seeded in 15ml medium in cell culture plates and 
rested for 24h. Medium was changed and the cells were infected with genomic particles 
per cell (GPC) of 10, 100 and 1000 and incubated for 48h. 
For uptake the wells were coated with A20 antibody for 1h at room temperature or at 4°C 
over night. Plates were 2 – 3 times washed with PBS/Tween20 1% and then incubated with 
10ml blocking buffer (Milk Powder 10%/Tween20 1%) at room temperature for 2h. The 
AAV library was then, diluted in 5ml blocking buffer submitted to the plates and incubated 
for 1 – 2 h at room temperature. Plates were then washed with 10ml PBS/Tween20 1% at 
least 15 – 20 times and 4x106 HeLa cells were seeded into the plates in 10ml medium. 
10ml fresh medium was added the next day and the cells were incubated at 37°C and 5% 
CO2 for another 24h. Cells were then harvested by scratching and the cell pellet was 
washed once with PBS and then resuspended in 500µl lysis buffer. The pellet was 
submitted to three rounds of freeze and thaw cycles and the supernatant was used for 
further analysis. Compare Cloning of insertion sequences of the AAV library into AAV 
vectors for sequencing. 
  
Selection of AAV library mutants on solid phase antibodies 
For selection the respective antibodies were coated to 15cm2 cell culture plate (TPP) at a 
concentration of 10 - 50µg/15cm2 per plate at 4°C over night. Plates were 2 – 3 times 
washed with PBS/Tween20 1% and then incubated with 10ml blocking buffer (Milk 
Powder 10%/Tween20 1%) at room temperature for 2h. The AAV library was then, diluted 
in 5ml blocking buffer submitted to the plates and incubated for 1 – 2 h at room 
temperature. Plates were then washed with 10ml PBS/Tween20 1% at least 15 – 20 times 
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and 4x106 HeLa cells were seeded into the plates in 10ml medium. 10ml fresh medium was 
added the next day and the cells were incubated at 37°C and 5% CO2 for another 24h. Cells 
were then harvested by scratching and the cell pellet was washed once with PBS and then 
resuspended in 500µl lysis buffer. The pellet was submitted to three rounds of freeze and 
thaw cycles and the supernatant was used for further analysis. Compare Cloning of 
insertion sequences of the AAV library into AAV vectors for sequencing. 
Cloning of insertion sequences of the AAV library into AAV vectors for 
sequencing 
DNA from 50µl from the supernatant after lysis and centrifugation was extracted by 
Qiagen DNeasy Tissue Kit and used for determination of genomic titers and amplification 
by PCR for further analysis. For genomic titers see Evaluation of AAV titers by Light 
Cycler PCR. For sequence analysis the DNA was amplified by PCR with the high fidelity 
Platinum Pfx DNA polymerase (Invitrogen) using 2µl each of the primers New SnaBI 1 
and BsiWI Back (each 10mM), usually with 5µl of the isolated DNA in a total volume of 
50µl. After PCR the DNA was purified by PCR Purification using the QIAGEN PCR 
Purification Kit, eluting the DNA in 40µl NEB4 buffer diluted 1:10 in two steps. 2µl were 
run on an agarose gel to control the PCR product. The purified DNA was then digested 
with SnaBI according to the manufacturer's manual (1.5-2h at 37°C) in a total volume of 
50µl. For digestion with BsiWI the DNA was purified again by PCR Purification Kit and 
eluted in 40µl NEB3, diluted 1:10. BsiWI was applied according to the manufacturer's 
manual (1.5-2h at 55°C) and again purified by PCR Purification. AAV backbone, pRC-
Kotin without ITR's or pwt with ITR's, was digested at the same time, 1µl of CIP was 
added before purification and incubated for 1h at 37°C for dephosphorylation. DNA 
concentration was determined by photometer and ligated with the AAV backbone, in most 
cases the pRC-Kotin, as described in Ligation of DNA fragments. After inactivation of 
Ligase activity, the ligated DNA was desalted by dialysis against H2O for 3h and then 
electroporated into XL-1 Blue MRF bacteria. After electroporation bacteria were 
suspended in 1ml of LB medium without antibiotics and put into the shaker for 1h. 
Bacterial solution was then diluted 1:1000 and applied to agar plates and incubated over 
night at 37°C. Single colonies were picked the next day and prepared for sequencing as 
described in DNA-Sequencing and sent to AGOWA. The sequences obtained by AGOWA 
were evaluated by computer using BioEdit. 
For the statistical verification of the frequency of the amino acids the χ2-test was applied. 
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Antibody-specific Dot Blot 
The AAV library mutants fished in selection on Omalizumab or anti-KLH, were 
packaged with GFP transgene and purified by Iodixanol density gradient and the capsid 
titers were determined by A20 ELISA. 1x105 and 5x105 capsid particles were dotted to a 
nitrocellulose membrane (Hybond, Amersham) using Dot Blot equipment. As positive 
control IgE antibody and KLH peptide are dotted, respectively, using 1µg protein in the 
first dilution step. The membrane is blocked in 5% Milk Powder/ PBS/ 1% Tween20 for 1h 
at room temperature and then incubated with Omalizumab or anti-KLH antibody, 
respectively, in a 1:1000 dilution in blocking solution overnight at 4°C. The membrane is 
washed 3x in PBS/1%Tween20 for 5min and then incubated with secondary antibody anti 
mouse IgGγ HRP control in a dilution of 1: 20000 for 1h at room temperature. The 
membrane is again washed with PBS/1%Tween20 and then developed in ECL advance 
solution (Amersham) for 5min at room temperature. The membrane is exposed to 
Hyperfilm (Amersham) and developed. After developing the membrane is stripped with a 
solution of 100mM Glycin pH2.5, 3x for 15min at room temperature and 3x in 
PBS/1%Tween20 for 15min at room temperature. The membrane is then again incubated 
with A20 antibody for detection of AAV capsids for 1h at room temperature. The 
membrane is washed and then incubated with secondary antibody anti mouse IgGγ HRP 
control in a dilution of 1: 20000 for 1h at room temperature and developed in ECL advance 
aolution (Amersham) and exposed to hyperfilm as above. 
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6. Abbreviations 
aa amino acid BSA bovine serum albumine 
AAV adeno-associated virus, bp base pair 
 specifically Cap capsid protein 
 adeno-associated virus type 2 CLL chronic lymphocytic leukemia
Ab  antibody CMV cytomegalovirus 
Ad Adenovirus Da Dalton 
  DMEM Dulbecco's Modified Eagle  
    Medium 
Amino acids  e.g. for example 
A (Ala) alanine  (Lat.: exempli gratia) 
C (Cys) cysteine ELISA enzyme-linked  
D (Asp) aspartate  immunosorbent assay 
E (Glu) glutamate FACS fluorescence-activated cell  
F (Phe) phenylalanine  sorting 
G (Gly) glycine FCS fetal calf serum 
H (His) histidine FGFR fibroblast growth factor 
I (Ile) isoleucine  receptor 1 
K (Lys) lysine Fig. figure 
L(Leu) leucine GFP green fluorescence protein 
M (Met) methionine GPC genomic particles per cell 
N (Asn) asparagine h hour 
P (Pro) proline HGFR hepatocyte growth factor  
Q (Gln) glutamine  receptor 
R (Arg) arginine HSPG heparan sulphate proteoglycan 
S (Ser) serine ITR inverted terminal repeat 
T (Thr) threonine kb kilobases 
V (Val) valine mAb monoclonal antibody 
W (Trp) tryptophan KLH keyhole limpet hemocyanin 
Y (Tyr) tyrosine   
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MHC major histocompatibility Rep viral regulatory protein 
 komplex RT room temperature 
min minute SDS sodium dodecyl sulphate 
MP milk powder Strep-POD Streptavidin-Peroxidase 
MOI multiplicity of infection TRS  terminal resolution site 
NPC nuclear pore complex VP viral protein (AAV capsid  
nt nucleotide  protein) 
ori origin of replication wtAAV wild-type AAV 
ORF open reading frame   
PEG-mal polyethylenglycol-maleimide   
rAAV recombinant AAV   
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